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A novel mutation in thea-Synuclein (a-Syn) gene “G51D” was recently identified in two familial cases exhibiting
features of Parkinson’s disease (PD) and multiple system atrophy (MSA). In this study, we explored the impact of
thisnovelmutationontheaggregation,cellularandbiophysicalproperties ofa-Syn, inanattempt tounravelhow
this mutant contributes to PD/MSA. Our results show that the G51D mutation significantly attenuates a-Syn
aggregation in vitro. Moreover, it disrupts local helix formation in the presence of SDS, decreases binding
to lipid vesicles C-terminal to the site of mutation and severely inhibits helical folding in the presence of
acidic vesicles. When expressed in yeast, a-SynG51D behaves similarly to a-SynA30P, as both exhibit impaired
membrane association, form few inclusions and are non-toxic. In contrast, enhanced secreted and nuclear
levels of the G51D mutant were observed in mammalian cells, as well as in primary neurons, where a-SynG51D
was enriched in the nuclear compartment, was hyper-phosphorylated at S129 and exacerbated a-Syn-induced
mitochondrial fragmentation. Finally, post-mortem human brain tissues ofa-SynG51D cases were examined, and
revealed only partial colocalization with nuclear membrane markers, probably due to post-mortem tissue delay
and fixation. These findings suggest that the PD-linked mutations may cause neurodegeneration via different
mechanisms, some of which may be independent of a-Syn aggregation.
INTRODUCTION
Parkinson’s disease (PD) is the second most common neurode-
generative disorder characterized by severe loss of dopamine
producing neurons in the substantia nigra of the brain. The pres-
ence of intracellular inclusions termed “Lewy bodies” compris-
ing misfolded and aggregated proteins within surviving neurons
has been long established as a neuropathological hallmark of
PD (1). The discovery that mutations in the a-Synuclein
(a-Syn) encoding gene “SNCA” cause autosomal dominant
familial PD two decades ago (2) led to the identification of the
a-Syn protein as the major component of Lewy bodies (3).
a-Syn is a natively unfolded presynaptic protein that is
involved in regulating neurotransmitter release, synaptic plasti-
city and intracellular trafficking within the ER/golgi network
(4,5). Although a-Syn exhibits no stable secondary structure in
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solution (6), it adopts ana-helical conformation upon interaction
with unilamellar vesicles comprising negatively charged lipids
(7–10). Moreover, upon aggregation, a-Syn undergoes struc-
tural changes, self-associates and forms b-sheet rich oligomeric
species and amyloid fibrils (11).
Duplications/triplications (12,13) and several missense point
mutations of the SNCA gene have been identified in patients
having a familial history of PD, namely A53T, A30P and
E46K (2,14,15). Recently, two new familial mutations in
a-Syn’s coding sequence were discovered at residues H50Q
and G51D (16–18). Whereas the former was linked to late-onset
PD, the G51D mutation was associated with early onset of
disease and neuropathological features of both PD and multiple
system atrophy (MSA); an a-synucleinopathy showing glial
cytoplasmic inclusions (GCIs) in oligodendrocytes in addition
to neuronal cytoplasmic inclusions. Interestingly, these two
mutations showed different effects on a-Syn aggregation
in vitro, with the H50Q slightly enhancing aggregation (19),
and the G51D mutant (a-SynG51D) exhibiting slower oligomer-
ization propensity compared to the WT protein (a-SynWT) (18).
Nevertheless, the precise mechanism by which the G51D muta-
tion causes PD/MSA remains unknown.
In this study,weperformeddetailedstudies toexamine theeffect
of the G51D mutation on the structure, aggregation, membrane
binding and phosphorylation of a-Syn, both in vitro and in cells.
In addition, we investigated the impact of this mutation on
a-Syn’s subcellular localization, secretion and toxicity using dif-
ferent mammalian cell lines and primary neurons. Finally, we
extended our analysis to post-mortem human brain samples of
a-SynG51D cases, where we performed thorough immunohisto-
chemical analysis of the subcellular localization of a-SynG51D.
Our results suggest that, unlike other PD-linked mutations which
have been shown to enhance a-Syn oligomerization and/or fibril
formation, the G51D mutant aggregates significantly slower
than a-SynWT in vitro, and forms amorphous aggregates at early
aggregationstages. Inaddition, theG51Dmutantexhibits impaired
membrane binding in vitroand in yeast, is secreted more rapidly by
mammalian cells and is enriched in the nuclear compartment of
cell lines and primary neurons; an effect that is concomitant
with enhanced nuclear S129 phosphorylation and exacerbated
mitochondrial fragmentation. Notably, we could not detect any
nuclear a-SynG51D in post-mortem human brains, probably due
to the post-mortem delay and/or tissue fixation and processing
procedures.
RESULTS
The G51D mutation does not significantly affect the
structure of free a-Syn in aqueous buffer
We first assessed whether the G51D mutation influences the native
structure ofa-Syn in vitro. After showing that the two proteins run
as a single band on SDS–PAGE,exhibit the samerandom coil sec-
ondary structure signal (as shown by circular dichroism spectros-
copy; CD) and behave as monomeric proteins (as determined by
MALS; Supplementary Material, Fig. S1A–E), we examined
the structure of a-SynG51D in aqueous solution compared to
a-SynWT using NMR spectroscopy. The 1H,15N-HSQC spectrum
of the mutant appeared to be very similar to that ofa-SynWT and a
comparison of amide group chemical shifts (Supplementary
Material, Fig. S1F) confirmed that differences in spectra are
localized to the few (+5) residues surrounding the mutation
site, although small chemical shift perturbations extend slightly
further C-terminal to the mutation site. Analysis of the secondary
structure propensity of a-SynG51D via alpha-carbon secondary
shifts (Supplementary Material, Fig. S1G) showed no significant
loss or gain of secondary structure compared to a-SynWT,
despite some small perturbations at the mutation site. These data
show that the G51D mutation does not significantly affect the
overall disordered structure of a-Syn in aqueous solution. The
G51D mutation also does not significantly perturb transient long-
range N- to C-terminal contacts known to occur ina-SynWT (Sup-
plementary Material, Fig. S1H).
The G51D mutation attenuates a-Syn aggregation and
alters the structure of a-Syn aggregates in vitro
In order to compare the kinetics of aggregation of a-SynWT
versus a-SynG51D, we performed in vitro aggregation experi-
ments by incubating each of the proteins for several days at
378C under shaking conditions. Strikingly, and as presented in
Figure 1, the aggregation of the G51D mutant was significantly
slower than that of the WT protein.a-SynWT showed an increase
in Thioflavin-T (ThT) signal already after 3–6 h incubation, and
the plateau was reached after 36 h (Fig. 1A), whereas the ThT
signal of the G51D mutant began to increase only after 12 h of
incubation and the plateau was reached after 48 h. Moreover,
the final absolute value of the plateau ThT signal of the G51D
mutant was consistently about two to three times less than that
of a-SynWT. As a second readout to assess fibril formation, we
used a sedimentation assay which allows quantifying the loss
of soluble protein as a function of time. In line with our ThT
data, the sedimentation assay showed that a-SynWT converted
to insoluble aggregates slightly faster than the G51D mutant
(Fig. 1B). Although there was no soluble protein left after 72 h
of incubation ofa-SynWT, solublea-SynG51D was still observed
after 120 h of incubation. However, the difference in aggrega-
tion propensity observed using this assay was not as prominent
as shown by ThT.
TEM micrographs revealed that although small oligomeric
species were observed for both proteins at early time points,
after 3 h of incubation those species readily converted into
fibrils in the case ofa-SynWT, but not fora-SynG51D, which con-
tinued to form larger amorphous aggregates (Fig. 1C). In fact,
fibrils of the G51D mutant were first observed only after 24 h
of incubation. The large ThT-negative amorphous aggregates
observed with the G51D mutant are likely to precipitate when
centrifuged (i.e. leading to loss of soluble protein) which could
explain why the G51D mutant exhibited longer fibrilization
lag phase by ThT, despite having comparable loss of soluble
species in the sedimentation assay. Notably though, at longer in-
cubation times these amorphous aggregates seem to convert into
fibrils, as they are no longer observed by TEM, and very little
a-Syn remains in the soluble fraction. Consistent with the
faster aggregation rate of the WT protein, however, CD spectros-
copy showed that while the secondary structure ofa-SynWT was
converted from random coil to b-sheet conformation within the
first 12 h of incubation, a-SynG51D conversion to b-sheets was
delayed and completed only after 48 h (Fig. 1D).
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The G51D mutation disrupts local helix formation
in the presence of SDS and decreases binding to lipid
vesicles C-terminal to the mutation site
The G51 residue lies within the N-terminal region ofa-Syn which
mediatesa-helix formation upon interaction with acidic vesicles.
Therefore, we investigated the effect of the G51D mutation on
a-Syn lipid interaction by NMR and CD spectroscopy. As previ-
ously established,a-SynWT adopts a broken-helix structure in the
presence of spheroidal SDS micelles in which the N-terminal
100 residues form two antiparallel helices (helix-1 and
helix-2) connected by a short linker (10,20–22). Comparison of
1H,15N-HSQC spectra ofa-SynWT anda-SynG51D in the presence
of 40 mM SDS shows significant spectral changes (Fig. 2A) and a
residue-by-residue comparison of amide group chemical shifts
(Fig. 2B) reveals that differences are not only centered on the mu-
tation site but extend 15 residues both N- and C-terminal to the
position of the mutation. Analysis of the alpha-carbon secondary
shifts (Fig. 2C) shows that residues 45–55, corresponding to
the N-terminal end of helix-2, exhibit decreased helicity in the
G51D mutant, which may reflect N-terminal fraying of helix-2
in the presence of the glycine to aspartate mutation.
NMR spectroscopy was also used to examine the effect
of the G51D mutation on a-Syn binding to lipid vesicles in
a residue-specific manner, taking advantage of the fact that
a-Syn residues participating in binding become NMR-invisible
(23,24). Thus, in a partial-binding regime, the intensity decrease
of amide cross-peaks in the presence of vesicles can report on the
lipid-bound population of that particular region of the protein.
When incubated with 20:1 lipid:protein small unilamellar
vesicles (SUVs) composed of 15:25:60 DOPS:DOPE:DOPC,
a-SynG51D shows a qualitatively similar binding profile to that
of a-SynWT (Fig. 2D), with the N-terminal 100 residues
showing decreased intensity resulting from binding. However,
the decrease in intensity for residues 45–100 is notably less
for the mutant protein. Interestingly, this region corresponds
roughly to helix-2 of the broken-helix form of a-Syn.
Next, we compared the ability of a-SynWT versus a-SynG51D
to form a-helical structure upon interaction with different ratios
of negatively charged POPG vesicles (1:0, 1:0.5, 1:2, 1:5 and
1:10, w/w) by CD. As previously reported (7,8), we observed
an increase in a-SynWT a-helical content with increasing
POPG proportions (Fig. 2E). Strikingly, the G51D mutant exhib-
ited significantly reduced propensity to form a-helices in the
presence of vesicles, even at high POPG ratios. The capacity
of a-SynG51D to form a-helices was further investigated using
trifluoroethanol (TFE), a solvent that favors helix formation of
intrinsically helical motifs. As such, comparing CD spectra of
a-SynG51D mixed with POPG vesicles or with TFE enables us
to differentiate between the intrinsic helical propensity of
a-SynG51D and conformational changes induced by its inter-
action with acidic vesicles, which correlate with biological activ-
ity (25). The inherent capacity of a-SynG51D to form a-helices
was not abrogated, as demonstrated by the fact that it can still
adopt ana-helical conformation in the presence of TFE (Supple-
mentary Material, Fig. S2A), hence demonstrating that the
G51D mutation interferes specifically with a-Syn interaction
with negatively charged vesicles.
Figure 1.The G51D mutation attenuatesa-Syn aggregation in vitro. Recombinanta-SynWT ora-SynG51D were incubated at 378C under shaking conditions, and the
kinetics of aggregation of both proteins were followed by: (A) ThT+SEM (∗P , 0.05, ∗∗P , 0.01, ∗∗∗P, 0.001, n ¼ 3), (B) quantification of remaining soluble
protein+ SEM(the differences between the WT and mutant are non-significant, for all time points,n ¼ 3), (C) transmission electron microscopy (scale bar is 200 nm)
and (D) circular dichroism. In all used assays, we observed attenuation of a-SynG51D aggregation kinetics compared to a-SynWT.
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Partially folded conformations of a-Syn in the presence
of intermediate protein to lipid ratios have been reported to
favor membrane-induced aggregation (24,26–28), while the
strong a-helical conformation of the protein observed in high
excess of lipids was shown to inhibit the aggregation process.
As such, and since G51D shows partially folded states even in
excess of lipids, we hypothesized that membrane-driven aggre-
gation should be favored at all protein to lipids ratios. To test
this hypothesis, we incubateda-SynWT and a-SynG51D with dif-
ferent ratios of POPG vesicles (1:0, 1:0.5, 1:2, 1:5 and 1:10, w/w)
under shaking conditions. As previously reported (29,30), we
observed that a-SynWT aggregation is favored in the presence
of intermediate protein to lipid ratios, while it is inhibited at
high ratios, due to the strong a-helical conformation (Supple-
mentary Material, Fig. S2B). Conversely, a-SynG51D which
only forms partially folded states even in excess of lipids,
aggregation was enhanced at all tested ratios.
The G51D mutation impairs membrane association,
inclusion formation and toxicity of a-Syn in yeast
After having shown that the G51D substitution attenuatesa-Syn
aggregation and membrane binding in vitro, we sought to inves-
tigate whether this mutation influences the cellular properties of
a-Syn. Yeast cells have been used to model a-Syn biology and
pathobiology, to define mechanisms of aggregation and
toxicity, as well as to discover small molecule suppressors of
a-Syn-induced toxicity (31–37). Therefore, we first compared
the localization of the G51D mutant to that of a-SynWT, as well
as to the other PD-linked mutations, in yeast cells. To assess
this, C-terminally YFP-tagged proteins were expressed and visua-
lized by live fluorescence microscopy (34). Strikingly, whereas
WT, E46K, H50Q and A53Ta-Syn localized to the plasma mem-
brane or formed cytoplasmic vesicular membrane accumulations,
both the A30P and G51D mutants exhibited impaired membrane
association (Fig. 3A). Moreover, the vast majority of cells expres-
sing a-SynG51D or a-SynA30P did not form vesicular a-Syn foci
but showed mostly diffuse cytoplasmic localization (Fig. 3A).
To assess the effect of the impaired membrane binding on yeast
viability, serial dilutions of yeast transformants expressing WT
or mutant a-Syn fused to YFP were spotted on glucose- or
galactose-containing agar plates, and growth was assessed after
2 days. Whereas all transformants grew equally well on the
control glucose plates (noa-Syn expression), induction of expres-
sion in galactose-containing agar plates inhibited the growth of
yeast cells expressing WT, E46K, H50Q or A53T a-Syn but not
the G51D or A30P mutants (Fig. 3B). Importantly, spotting
assays performed with untagged a-Syn and mutants showed
similar results, indicating that the YFP-tag does not affect toxicity
in this model (Fig. 3C). Together, these results suggest that the
ability to associate with membranes is a component of a-Syn
toxicity in yeast.
Figure 2.The G51D mutation disrupts local helix formation in the presence of SDS, decreases binding to lipid vesicles C-terminal to the site of mutation and severely
inhibits helical folding in the presence of acidic vesicles. (A) 1H,15N-HSQC spectra ofa-SynWT (black) anda-SynG51D (red) in 40 mM SDS. (B) Plot of averaged amide
chemical shift difference [Ddamide ¼ p(12(DdHN2 + (DdN/5)2))] between the SDS-bound a-SynWT and a-SynG51D spectra as a function of residue number. The line
shows a three-residue average. (C) Plot of alpha-carbon secondary shifts (difference between measured chemical shift and random coil chemical shift) for a-SynWT
(black) and a-SynG51D (red) in the presence of 40 mM SDS as a function of residue number. The lines show three-residue averages. (D) Plot of the ratio of amide
cross-peak intensity in samples with 3 mM SUVs to the intensity in samples without SUVs for 150 mM a-SynWT (black) and a-SynG51D (red) by residue
number. (E) Circular dichroism of a-SynWT and a-SynG51D mixed with protein:lipid weight ratios of 1:0, 1:0.5, 1:2, 1:5 and 1:10. a-SynG51D (lower panel) shows
lower lipid biding propensity compared with a-SynWT (upper panel), as evidenced by the drastic decrease in alpha helical content at all tested ratios.
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The G51D mutation enhances the nuclear localization
of a-Syn in mammalian cells and primary neurons
We next investigated whether the G51D mutation influences the
properties of a-Syn in mammalian cells. First, we examined the
ability of WT versus mutant a-Syn to bind cellular membranes
in HEK cells by assessing colocalization with co-transfected
Mb-YFP (containing a palmitoylation domain of neuromodulin
that targets YFP to membranes) or ER-DsRed (containing
targeting sequence of calreticulin “KDEL retrieval sequence”
that targets DsRed to the ER). As a control, we performed the
same assay with a-SynA30P which showed impaired membrane
binding in our yeast model, and has been consistently reported
to exhibit reduced binding to lipids in vitro as well as in cells
(38–40). Immuno-labeling using the Syn-211 antibody showed
that all three variants exhibit mostly cytosolic localization, and
that neither the G51D nor A30P mutations perturb the partial colo-
calization of a-Syn with Mb-YFP or ER-DsRed (Fig. 4A),
indicating that this assay may not have the discriminatory strength
to distinguish differences in membrane binding of the three var-
iants. Strikingly though, biochemical fractionation of HEK cells
expressing WT or mutant a-Syn showed significant enrichment
of a-SynG51D in the nuclear fraction compared with WT or the
A30P mutant (Fig. 4B). In order to investigate this finding by
immunocytochemistry, we performed a thorough assessment of
the subcellular localization ofa-SynWT anda-SynG51D using dif-
ferent anti-a-Syn antibodies (epitopes depicted in Supplementary
Material, Fig. S3B) in transiently transfected HEK cells. Whereas
the three antibodies FL-140, Syn-208 and Syn-211 detected
mainly cytosolic distribution of a-Syn without detectable signal
in the nucleus (Supplementary Material, Fig. S3A), the Syn-1,
EP1646Y and SA-3400 antibodies detected additional nuclear
signal in some a-Syn expressing cells that was comparable in
intensity to that in the cytosol (Fig. 4C and Supplementary Mater-
ial, Fig. S3A). Importantly, more cells showing nuclear a-Syn
signal with the Syn-1 antibody were detected in HEK cells
Figure 3. The G51D mutation impairs a-Syn membrane binding, inclusion formation and toxicity in yeast. (A) Fluorescence microscopy was used to visualize the
localization of C-terminally YFP-taggeda-Syn fusion proteins expressed from a high-copy plasmid. Representative examples of localization patterns are shown in top
and bottom panels for each construct. Whereas WT, E46K, H50Q and A53Ta-Syn localized to the plasma membrane or cytoplasmic vesicular membrane accumula-
tions, the A30P and G51D mutations impaireda-Syn membrane association and exhibited mostly diffuse cytoplasmic distribution. (B) Serial dilutions of yeast trans-
formants expressing WT or mutanta-Syn YFP fusions were spotted on glucose- or galactose-containing agar plates, and growth was assessed after 2 days. Whereas the
transformants grew equally well on the control glucose plates (noa-Syn expression), expression of WT, E46K, H50Q or A53Ta-Syn inhibited growth and the A30P
and G51D mutations did not. (C) Spotting assay using untagged a-Syn constructs demonstrates similar results as with the YFP-tagged constructs shown in (B).
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Figure 4. Effect of the G51D mutation on a-Syn subcellular localization in mammalian cells and primary neurons. (A) Immunocytochemical analysis using the
Syn-211 antibody shows only partial colocalization of a-SynWT, a-SynG51D and a-SynA30P with the co-expressed cytoplasmic membrane marker (Mb-YFP;
upper panel) or endoplasmic reticulum marker (ER-DsRed; lower panel). (B) Subcellular fractionation of HEK cells expressing a-SynWT, a-SynG51D or
a-SynA30P reveals enriched localization of the G51D mutant in nuclear fractions compared witha-SynWT anda-SynA30P (upper panel). The total (input) and cytosolic
fractions establish that similar levels of a-Syn are expressed, and probing with HSP-90 and Parp-1 demonstrates equal loading, as well as purity of cytosolic versus
nuclear fractions, respectively. Densitometric quantification (lower panel, n ¼ 3) of a-Syn in nuclear fractions shows significant (P , 0.05) increase in a-SynG51D
enrichment in nuclear fractions compared toa-SynWT. (C) Immunocytochemical analysis using the Syn-1antibodyshows that cells expressinga-SynWT ora-SynG51D
exhibit either pure cytoplasmic localization, or cytoplasmic with additional comparable nuclear signal of a-Syn (upper panel). The lower panel shows quantification
of cells expressing a-SynWT or a-SynG51D and manifesting either of the two distributions. At least 800 cells per condition were quantified from four independent
coverslips (transfections), and the whole experiment was repeated twice. The asterisk represents significance at P , 0.05. (D) Living HEK cells expressing
mEOS2-a-SynWT or mEOS2-a-SynG51D were repeatedly photoconverted using a 461 nm laser in the cytosol (crossed circles), and imaged by time-lapse confocal
microscopy. The upper and lower panels for each condition show cellular fluorescence (488 and 568 nm) before (t ¼ 0) or after photoconversion (t ¼ 5 min), re-
spectively. Note that the photoconversion caused the bleaching of the cytosolic 488 nm signal. Scale bar denotes 2 mm. (E) Fluorescence intensity curves of nuclear
photoactivated WT or G51D mEOS2-a-Syn in cells photoconverted in the cytosol. For each condition, at least 25 cells were analyzed, and the experiment was repeated
twice. Each plot represents mean+SD for each time point of all photoactivation experiments. (F) Immunocytochemical analysis of neurons using the N-19 antibody
shows that botha-SynWT anda-SynG51D are localized in neuronal soma and neurites (left panel, low magnification), as evidenced by the co-staining with MAP-2. High
magnification images of soma (right panels) show that neurons expressinga-SynG51D exhibit more nuclear localization compared toa-SynWT. (G) Intensity profiles of
a-Syn and DAPI staining along red lines in (F) shows increased basal levels of a-SynG51D in neuronal nuclei compared to a-SynWT expressing neurons.
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expressing a-SynG51D compared to a-SynWT (Fig. 4C), hence
confirming our biochemical fractionation data.
To further investigate the increase in nuclear a-SynG51D
levels, we utilized the photoconvertable fluorescent protein
“mEOS2” (41). Normally, this protein emits bright green fluor-
escence at 506 nm. However, if illuminated at near-ultraviolet
wavelengths, its fluorescence is photoconverted to orange–red
(584 nm), hence allowing specific photoconversion and tracking
of mEOS2 tagged proteins. Therefore, we expressed constructs
encoding a-SynWT or a-SynG51D that are N- or C-terminally
fused to mEOS2 in HEK cells. At steady state, all proteins
showed cytosolic and nuclear localization (Supplementary Ma-
terial, Fig. S3C). Upon repeated photoconversion in a specific
region in the cytosol however, time-lapse confocal imaging
showed that photoconverted mEOS2-a-SynG51D is translocated
to the nucleus faster than its WT counterpart (Fig. 4D and Sup-
plementary Material, Videos S1 and S2). Quantification of the
intensities of photoconverted proteins in the nuclei of 25 cells
per condition further revealed that mEOS2-a-SynG51D is trans-
located at a higher rate compared with mEOS2-a-SynWT
(Fig. 4E). Notably though, the effect of the G51D mutation on
nuclear transport was much less pronounced when the
C-terminal mEOS2 fusion proteins were used to monitor
nuclear translocation (Supplementary Material, Fig. S3D).
This observation could be explained by previous studies impli-
cating the C-terminal domain in regulating the nuclear localiza-
tion of a-Syn (42–44).
To determine whether the G51D mutation affects the subcel-
lular localization ofa-Syn in neurons, we transiently transfected
primary hippocampal neurons and compared the localization of
a-SynWT and a-SynG51D using the different a-Syn antibodies
summarized in Figure S3B. All tested antibodies detected
a-Syn with in neuronal soma and neurites (Fig. 4F and Supple-
mentary Material, Fig. S4). Neuronal expression of a-Syn was
established by co-staining with the neuronal specific protein
MAP-2, and the SNAP-25 marker was also probed to reveal pre-
synaptic terminals, which showed similar partial colocalization
with neuritica-SynWT anda-SynG51D (Supplementary Material,
Fig. S4C). However, and in accordance with our observations in
HEK cells, whereas the Syn-208, Syn-211 and FL-140 anti-
bodies detected mostly cytosolic localization in neuronal
soma, the N19 (epitope N-terminal) and Syn-1 antibodies
revealed the additional nuclear signal in primary neurons
(Fig. 4F and Supplementary Material, Fig. S4). Importantly,
neurons expressing a-SynG51D exhibited again enhanced
nuclear localization compared with a-SynWT (Fig. 4G).
Nuclear a-SynG51D is hyper-phosphorylated
at S129 in primary neurons
Previous studies have shown that a-Syn phosphorylated at S129
is enriched in the nucleus (45–48). These observations, combined
with the fact that phosphorylation at S129 has been shown to
regulate a-Syn degradation, aggregation and toxicity (49), led
us to investigate whether the G51D mutation affects a-Syn
phosphorylation at S129, and conversely, whether differences in
S129 phosphorylation may explain the enhanced nuclear localiza-
tion of a-SynG51D. Therefore, we first transiently co-expressed
a-SynWT or a-SynG51D in HEK cells with PLK2 and GRK6;
two kinases known to efficiently phosphorylate a-Syn at S129
(46,50), and assessed phosphorylation biochemically and by im-
munofluorescence analysis. As shown in Figure 5A, HEK cell
lysates expressing a-SynWT or a-SynG51D together with GRK6
or PLK2 showed that both a-Syn forms are readily phosphory-
lated at S129. Moreover, co-expressing a-SynWT or a-SynG51D
with PLK2 (but not GRK6) induced significant degradation
of a-Syn, as recently described by our group for a-SynWT (51).
Similar results were obtained from triple immuno-labeling
experiments where a-SynWT and a-SynG51D were efficiently
phosphorylated at S129 by PLK2 and GRK6 (Fig. 5B). The speci-
ficity of the phospho-specific antibody used (WAKO) was con-
firmed by the fact that it did not stain a non-phosphorylatable
a-Syn mutant “a-SynS129A” when co-expressed with both
kinases (Fig. 5B).
In order to investigate the effect of the G51D mutation on
S129 phosphorylation in primary neurons, we performed double
immuno-labeling experiments on neuronal cultures expressing
a-SynWT or a-SynG51D using antibodies against total and pS129
a-Syn. As shown in Figure 5C and D, immuno-labeling using
the MJF-R13 or WAKO pS129 specific antibodies showed that
a-SynWT and a-SynG51D are both efficiently phosphorylated at
S129 by endogenous kinases in soma and neurites. Strikingly,
the a-SynG51D mutant exhibited much stronger nuclear pS129
signal compared with a-SynWT (Fig. 5C and D). This effect was
observed using the two pS129 specific antibodies, and even
when the anti-total a-Syn antibody “FL-140” did not detect the
enhanced nuclear localization of the mutant (Fig. 5D), hence
ruling out any non-specific signals arising from total a-Syn
imaging in the nucleus.
a-SynG51D exacerbates mitochondrial fragmentation
in primary neurons
We next assessed whether the G51D mutation confers any
toxic effect to a-Syn in neurons, and determined the effect
of the a-SynWT versus a-SynG51D expression on mitochon-
drial fragmentation; a robust phenotype indicative of cellular
stress that has been established for a-SynWT (52,53).
Notably, although both WT and mutant a-Syn provoked ab-
normalities in mitochondrial structure, as evidenced by detec-
tion of Mito-YFP positive fragmented and enlarged structures
(Fig. 6A), the effect of the G51D mutant was more pro-
nounced, as shown by the quantification of neurons expressing
a-Syn and exhibiting this abnormal mitochondrial phenotype.
To determine whether this affected neuronal viability, we
transiently expressed a-SynWT or a-SynG51D in primary
neurons, and monitored the number of dead cells over time
using the Sytox green exclusion assay. In line with previous
reports (54,55), expression of a-SynWT did not provoke prom-
inent toxicity (Fig. 6B). Moreover, a-SynG51D transfection
showed similar levels of Sytox green fluorescence compared
to transfection with the empty vector control, hence suggest-
ing that a-SynG51D expression does not lead to neuronal
death per se.
The G51D mutation enhances a-Syn secretion
by differentiated neuroblastoma cells
Given that a-Syn has been consistently reported in biological
fluids such as CSF (56,57), blood plasma (58–60) and saliva
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(61,62), and increasing evidence from in vivo and cell culture
models supports a role for extracellular a-Syn in seeding and
spreading pathology in a prion-like manner (63–66), we
probed the effect of the G51D mutation on a-Syn secretion by
differentiated SHSY5Y neuroblastoma cells. Strikingly,
analysis of the conditioned media (CM) derived from cells over-
expressing WT or mutant a-Syn showed increased levels
of secreted monomeric and high molecular weight (HMW)
a-SynG51D compared to the WT protein (Fig. 7A and B),
although similar levels of both proteins were detected in cellular
lysates. To rule out the possibility of the G51D mutant being
more toxic and hence leading to increased a-Syn levels in CM
due to membrane permeabilization, we measured the levels of
a cytosolic housekeeping protein “lactate dehydrogenase
(LDH)” in CM. Using this assay, we did not observe any signifi-
cant difference in LDH release between a-SynWT and
a-SynG51D (Fig. 7C), suggesting that the G51D mutation pro-
motes a-Syn secretion by SHSY5Y cells.
Immunohistochemical analysis of post-mortem human
brains reveals Thioflavin-S positive a-SynG51D that only
partially colocalizes with nuclear membrane markers
Finally, we set out to assess the effect of the G51D mutation on
the distribution of a-Syn in human brains. Therefore, double
immunofluorescence analysis of a-Syn with nuclear envelope
markers (Lamin A/C) was performed on paraffin embedded sec-
tions of human post-mortem a-SynG51D cases (n ¼ 3). Notably,
only partial colocalization of a-Syn with Lamin A/C was appar-
ent, particularly in regions which have an abundant accumula-
tion of annular type inclusions, including the posterior frontal
cortex and the dentate fascia (Fig. 8A). This colocalization
was less apparent in regions having greater populations of
NFT-like inclusions such as the CA1 of the hippocampus
(Fig. 8B). Importantly, this experiment was repeated using
different antibodies (Figure S3B), and again, no evidence of
strong a-Syn expression within the nucleus was detected (data
not shown).
To investigate the conformational state of a-SynG51D, double
immunofluorescence microscopy of a-Syn with Thioflavin-S
was performed on paraffin embedded sections of frontal and
temporal cortex of post-mortem brain tissues of a-SynG51D
cases. Sections double stained with a-Syn and Thioflavin-S
examined by confocal microscopy confirmed the presence of
a-SynG51D in an amyloid conformation within inclusions
(Fig. 8C).
DISCUSSION
The G51D mutation attenuates a-Syn aggregation in vitro
Given that a-Syn aggregation into amyloid fibrils has been
established as a central event in the pathogenesis of PD, we
Figure 5.The G51D mutation enhances nucleara-Syn S129 phosphorylation in primary neurons. (A) Western blot analysis shows that botha-SynWT anda-SynG51D
are readily phosphorylated by PLK2 or GRK6 at S129, as HEK cells co-overexpressing a-Syn and each of these kinases show prominent phosphorylation at S129.
Moreover, co-expressing a-SynWT or a-SynG51D with PLK2 induced significant degradation of a-Syn as recently described by our group for a-SynWT (51). As con-
trols, HEK cells were transfected witha-SynWT ora-SynG51D together with empty vector, and actin was used as a loading control. (B) Triple immuno-labeling of HEK
cells co-expressing a-SynWT or a-SynG51D with PLK2 (left panel) or GRK6 (right panel) shows that both proteins are efficiently phosphorylated at S129 by these
kinases. The N19 antibody (N-terminal epitope) was used to detecta-Syn, and the specificity of the used phospho-specific antibody (WAKO anti-pS129) was estab-
lished as the non-phosphorylatable S129A mutant shows no pS129 signal when co-expressed with PLK2 or GRK6. Note that in the case of PLK2 overexpression, cells
expressing similar levels of a-Syn were imaged in order to allow comparison of subcellular distribution. (C and D) Double immuno-labeling of neurons expressing
a-SynWT ora-SynG51D using the N19 antibody for totala-Syn and MJF-R13 for pS129 (C), or FL-140 antibody for totala-Syn and WAKO for pS129 (D) shows that
botha-SynWT anda-SynG51D are efficiently phosphorylated at S129by endogenous kinases in the soma and terminals (left panels),witha-SynG51D exhibiting stronger
nuclear pS129 signal compared to a-SynWT (C and D; right panels).
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Figure6.The G51D mutationexacerbates mitochondrial fragmentation in primary neurons. (A) Immunocytochemical analysis using the Syn-211antibody shows that
botha-SynWT and a-SynG51D expressing neurons exhibit fragmented mitochondria compared with neurons transfected with empty plasmid (upper panel). To delin-
eate mitochondria, the mitochondrial marker Mito-YFP was co-expressed witha-Syn encodingvectors.Quantification of neuronsco-expressinga-Syn and Mito-YFP
showed that a-SynG51D expression exacerbates mitochondrial fragmentation, as more neurons manifesting Mito-YFP clumps (larger than in 1 mm in diameter) were
identified upon a-SynG51D expression (lower panel). The asterisk represents significance at P , 0.05 (at least 25 neurons per condition were quantified and the ex-
periment was performed three independent times). (B) The Sytox green dye exclusion assay was used to assess the amounts of dead neurons upon transfection with
empty vector, a-SynWT or a-SynG51D for 24, 48 and 72 h. The upper panel shows representative images of neurons 24 h post transfection, stained with the Syn-211
anti-human a-Syn antibody, and the anti-MAP2 antibody to reveal transfected and total neurons, respectively. Quantification (n ¼ 3) of Sytox green fluorescence
intensity over time is shown in the lower panel. Neurons treated with 200 mM H2O2 for 24 h were used as positive controls showing toxicity (i.e. high Sytox green
fluorescence).
Figure 7. The G51D mutation enhances a-Syn secretion by neuroblastoma cells. (A) Biochemical analysis of SHSY5Y cells expressing a-SynWT or a-SynG51D
shows that although similar levels of both proteins are expressed in total cellular lysates, more monomeric and HMW a-SynG51D is detected in extracellular CM.
Actin was used as a housekeeping gene denoting equal protein loading of cellular lysates. (B) Densitometric quantification (n ¼ 3) of monomeric a-Syn released
into CM (normalized against total a-Syn levels in Tris-soluble fractions) shows 50% increase in secreted levels of a-SynG51D compared to a-SynWT at
P, 0.01. (C) Quantification (n ¼ 3) of released LDH in CM shows no significant difference between a-SynWT and a-SynG51D.
Human Molecular Genetics, 2014, Vol. 23, No. 17 4499
first assessed the impact of the recently reported G51D mutation
on a-Syn aggregation. Strikingly, the aggregation of a-SynG51D
in vitro was significantly attenuated compared with a-SynWT as
assessed by ThT binding and CD spectroscopy. However, ana-
lysis of remaining soluble content revealed less difference in
aggregation propensity between the G51D mutant and
a-SynWT. This finding was confirmed and explained by TEM
imaging of the aggregates formed by both proteins. At early
time points, a-SynG51D forms amorphous aggregates that are
ThT negative but readily sediment upon centrifugation. As
such, these results suggest that the G51D mutation favors the for-
mation of “off-pathway” amorphous aggregates, which re-enter
the amyloid pathway upon depletion of monomeric a-Syn.
A similar, however, less prominent attenuation in fibrilization
has been reported in the case of the A30P mutant (67–69),
whereas all other reported mutations (A53T, E46K and the re-
cently described H50Q) showed enhanced aggregation propen-
sities. In fact, increased levels of amorphous aggregates were
also demonstrated for the A30P mutant (67), suggesting that
both G51D and A30P mutants may share similarities in
aggregation behavior. Notably, one of the two studies initially
reporting the identification of the G51D mutation showed no
effect on a-Syn aggregation in vitro (18). Given that the aggre-
gation studies carried out by Lesage et al. (18) were performed
at a high protein concentration (100 mM), compared with the
relatively low concentration used in this study (10 mM), we
Figure 8. a-SynG51D from post-mortem human brains is Thioflavin-S positive and partially colocalizes with nuclear envelope proteins. (A) Representative double
immunofluorescence images of a-Syn (red) and Lamin A/C (green) reveal annular type inclusions of the dentate fascia (DF) of post-mortem a-SynG51D cases
which partially colocalize with Lamin A/C. (B) a-Syn inclusions having NFT-like morphology of the CA1 region show less colocalization with Lamin A/C.
Scale bars represent 50 mm. (C) a-SynG51D colocalizes with Thioflavin-S indicating amyloid conformation. Representative double immunofluorescence images
of a-Syn expression (red) and Thioflavin-S (green) staining in DF and CA1 regions of post-mortem a-SynG51D cases.
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assessed whether this discrepancy was due to the difference in
concentration. However, even when increasing the concentra-
tion to 100 mM, the G51D mutant exhibited significantly
slower aggregation kinetics compared toa-SynWT (Supplemen-
tary Material, Fig. S2C).
The G51D mutation impairs a-Syn interaction with SDS
micelles and lipid vesicles in vitro, attenuates membrane
binding in yeast and enhances secretion in mammalian cells
Given that the glycine 51 residue is located in a region that is
known to become helical upon interaction with vesicles (Supple-
mentary Material, Fig. S5A) (7,8), we investigated the effect of
the G51D mutation on a-Syn membrane binding in vitro. Both
NMR and CD studies revealed that although the G51D mutation
does not have a significant effect on the structure of the free
protein in aqueous solution, the substitution of a glycine for a
negatively charged aspartate has a significant effect on a-Syn
membrane interactions. In the presence of the anionic detergent
SDS, which has been commonly used as a membrane mimic for
a-Syn structural studies, the N-terminal region of a-SynWT
forms a broken-helix state composed of two antiparallel
helices connected by a short linker (residues 37–45) (10,20–22).
The G51D mutation, which occurs near the N-terminal end of
helix-2, significantly decreases the helicity of residues 45–55,
suggesting a destabilization effect on the interactions of
helix-2 with the micelle surface, possibly resulting in N-terminal
fraying. This destabilization is likely a result of the introduction
of a negative charge in the apolar face of helix-2 (10,20) (Supple-
mentary Material, Fig. S5B), which is likely to perturb the ability
of this region of the amphipathic helix to interact with the hydro-
phobic interior of the detergent micelle.
When a-Syn binds to lipid vesicles, it adopts an extended-
helix conformation in which the linker region between helix-1
and helix-2 of the micelle-bound state converts to a helical con-
formation (70), fusing the two separate helices into one long un-
interrupted helix. Models of the extended-helix state (20,71)
indicate that the G51D mutation would again introduce a
charged residue into the apolar face of the helix (Supplementary
Material, Fig. S5A). In contrast to what is observed for the
micelle-bound state, however, our NMR data reveal that the
effect of the G51D mutation is not limited to perturbing local
binding, but instead leads to decreased binding of the entire
region C-terminal to the mutation. This indicates that the
helix-2 region is essentially detached from the vesicle surface,
while the N-terminal helix remains attached. Consistent with
this observation, CD analysis of a-Syn incubated with different
POPG lipid ratios revealed that a-SynG51D shows significantly
reduced lipid biding propensity compared to the WT protein.
We have previously suggested (72,73) that helix-1 and helix-2
can act as partially independent binding modules on vesicle
surfaces, and a variety of experimental observations support the
existence of vesicle-binding modes where helix-1 (or parts
thereof) are bound while helix-2 is not (24,26–28). Such states
have also been proposed to facilitate membrane-induced aggrega-
tion of a-Syn (26,49,72). It appears that by disrupting protein–
membrane interactions in the N-terminal region of helix-2, the
G51D mutation favors the formation of such conformations.
Consistent with this hypothesis, we show that membrane-induced
aggregation of a-SynG51D is favored at all protein to lipid ratios,
while the aggregation of a-SynWT is inhibited in large lipid
excess, due to the strong a-helical conformation of the protein.
These results further confirm that partially folded states favor
a-Syn aggregation and suggest that the lack of strong a-helical
conformation of the G51D mutant could allow its aggregation in
the presence of lipids and hence explain to some extent its role
in disease.
In order to determine whether the G51D mutation similarly
affects a-Syn binding to biological membranes, we first
expressed WT and mutant a-Syn (C-terminally YFP-tagged)
in yeast cells. Strikingly, and in line with our in vitro data, the
G51D mutation impaired a-Syn’s membrane binding ability,
and was not toxic to the yeast cells, an effect that was very
similar to that of the A30P mutant (31). From a functional per-
spective, it is interesting to compare the G51D mutation’s
effects on a-Syn membrane interactions with those of the
A30P mutation, which until now was the only known disease-
linked mutation that significantly influenced this aspect of
a-Syn physiology. Given the similarities in aggregation and
membrane binding behavior of a-SynA30P and a-SynG51D, one
could hypothesize that both mutants contribute to Parkinson’s
pathology via common mechanisms. In fact, although located
in different helical segments (A30P is located in helix-1 while
G51D is located in helix-2), they both destabilize the formation
of their cognate helices, leading to a partly helical state at the
membrane. Notably, we were not able to detect differences in
membrane binding of a-SynG51D compared with a-SynWT
when overexpressed in HEK cells. This is likely due to our
assay having weak discriminatory strength in these cells, espe-
cially that as we also could not detect reduced membrane
binding of the A30P mutant, which has been extensively
shown to exhibit reduced membrane binding in vitro and in
cell free systems (38,40). In line with this, a previous report
showed that overexpressed a-SynA30P in mammalian HeLa
cells exhibits reduced binding to lipid droplets formed upon
treatment with high concentration of fatty acids, albeit not
showing major differences in overall distribution without such
treatment (39). Therefore, it remains unclear whether the mem-
brane binding potential of a-SynG51D is affected in mammalian
cells upon mere overexpression alone.
Given that a-Syn has been shown to be secreted via vesicle-
mediated exocytosis, and the increasing interest in the role of
extracellular a-Syn in seeding and spreading of pathological
a-Syn, we investigated whether the G51D mutation influences
a-Syn cellular secretion. Strikingly, increased levels of secreted
monomeric and HMW a-SynG51D were detected in CM of
SHSY5Y cells. This effect was not due to non-specific release
ofa-Syn due to cell death, as LDH levels in CM were not affected
by a-Syn overexpression, and HMW a-Syn was not detected in
cytosolic extracts. Taken together, these results suggest that,
although a-SynG51D localization at the membrane does not
seem to differ from that of the WT protein, its folded state,
which is affected by the glycine to aspartate mutation, could
be leading to a partially folded conformation that potentially
enhances its active secretion in SHSY5Y cells, and that mem-
brane binding could be an important regulator of this process.
On another note, until recently, it was believed that oligodendro-
glia do not express a-Syn and therefore the origin of the a-Syn
contributing to GCIs in MSA was uncertain. Although it now
seems that oligodendrocytes can express a-Syn mRNA (74),
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there may also be a contribution from extracellular a-Syn, as it
has been demonstrated that cultured oligodendrocytes can take
up neuron-derived a-Syn from the extracellular medium (75).
Thus, an increase in secretion of a-SynG51D could explain the
finding of GCI-like inclusions in G51D mutation cases.
a-SynG51D exhibits enhanced nuclear localization in HEK
cells, in primary neurons but not in post-mortem human
brains of a-SynG51D cases
a-Syn was first discovered as a neuronal protein having pre-
synaptic as well as nuclear localization (76). Since then,
although the physiological role of a-Syn at the synapse has
been extensively investigated and a regulatory role for a-Syn
in presynaptic vesicle cycling and neurotransmitter release has
been proposed (77–81), few studies have focused on the func-
tion of a-Syn within the nucleus. The nuclear distribution of
a-Syn remains somewhat controversial, as conflicting results
were obtained regarding the existence of endogenous a-Syn
within neuronal nuclei (82–85). Based on published reports
(48), as well as our data from this study, this discrepancy could
be partially due to the use of different antibodies to detect
a-Syn in various studies. In fact, our results show that some anti-
bodies (such as Syn-1, EP1646Y and SA-3400) are more sensi-
tive to detecting nucleara-Syn than others (i.e. FL-140, Syn-208
and Syn-211), depending on the epitope they recognize, espe-
cially as it has been suggested that the a-Syn species in the
nucleus could be truncated (86,87), and hence not detectable
by some of the commonly used antibodies.
In this study, we observed prominent nuclear enrichment of
the G51D mutant compared with a-SynWT in mammalian
HEK cells using three independent approaches; biochemical
subcellular fractionation, immunocytochemistry using anti-
bodies detecting nuclear a-Syn as well as live imaging. Import-
antly, although overexpressed a-SynG51D exhibited enhanced
nuclear localization in primary cultured neurons, immunohisto-
chemical analysis of post-mortem human brain tissues of
a-SynG51D cases did not reveal comparable nuclear signal for
a-Syn. This lack of detection of nuclear a-Syn may be due to
several technical issues. First, nuclear a-Syn may exist at a
level which is below the sensitivity of the immunofluorescence
technique, compared with the transient and acute overexpression
of a-Syn that was performed in our cell and neuronal culture
models. Secondly, the post-mortem delay period may affect
the steady-state distribution of a-Syn, hence decreasing its ef-
fective nuclear concentration. Thirdly, nucleara-Syn in paraffin
sections may be physically inaccessible to the a-Syn antibodies
that we have investigated, as this may be influenced by fixation
time or require greater disruption of cell membranes. Finally,
the conformation of nuclear a-Syn in human brains may be
altered so that none of the antibodies we tested were capable of
recognizing the protein in this subcellular compartment. There-
fore, the subcellular localization of the a-SynG51D should be
further investigated and verified in post-mortem human brain
tissues of a-SynG51D cases, by optimizing protocols that allow
robust detection of nuclear a-Syn by immunohistochemistry
and biochemical assays.
It has been previously shown that the PD-linked mutations
A30P and A53T exhibit increased nuclear targeting as well as
enhanced speed of shuttling between the nucleus/cytoplasm in
cell culture (44,88). Moreover, a recent study demonstrated
that, in addition to the C-terminal domain that has been long
associated with nuclear accumulation (42), amino acid residues
1–60, which span the region harboring all four PD-linked muta-
tions, is indispensable for a-Syn nuclear import (43). Notably,
we did not observe similar nuclear enrichment of the A30P
mutant by biochemical fractionation of HEK cells. This suggests
that the increased nuclear localization ofa-SynG51D is not solely
due to deficits in membrane binding, and that other molecular
properties of this mutant may be promoting its aberrant distribu-
tion in our over expression models.
Given that several proteins associated with neurodegeneration
have been found to exert their pathogenic effects when localized
in the nucleus (89–92), it could be that the nuclear localization
of PD-linked mutant a-SynG51D is at least a partial mediator of
neurotoxic effects. In line with this, the handful of studies that
have convincingly demonstrated nuclear localization of a-Syn
in transfected mammalian cells, cultured primary neurons and
in vivo have mainly proposed a neurotoxic function for a-Syn in
neuronal nuclei that is not necessarily dependent ona-Syn aggre-
gation. For instance, an elegant study by Kontopoulos et al. (88)
showed that a-Syn binds directly to histones and reduces
histone H3 acetylation, promoting toxicity both in cell culture
and transgenic Drosophila. Similarly, an independent study by
Goers et al. (93) showed using mice midbrain sections, that para-
quat up-regulates a-Syn expression, nuclear localization and
colocalization with acetylated H3 histones. Importantly, although
the same report demonstrated thata-Syn interacts with histones in
vitro, and that histones dramatically accelerate a-Syn fibrilliza-
tion, nuclear a-Syn fibrils were not detected in paraquat treated
brains, suggesting that the pathogenic effects of nuclear a-Syn
localization could be independent of a-Syn aggregation. Further
studies supported this notion, as they consistently reported
increased nuclear accumulation ofa-Syn in response to oxidative
stress in dopaminergic neurons (86), which in turn enhances the
susceptibility of dopaminergic cells (87), probably by accelerat-
ing the cell cycle (43), or the protein’s ability to modulate the tran-
scription of PGC-1a; a master mitochondrial transcriptional
activator (94). Therefore, future studies should aim at elucidating
the cellular factors promoting enhanceda-SynG51D nuclear local-
ization, as well as assessing the result of this enhanced accumula-
tion on PD pathology in different cellular and in vivo models.
Nuclear a-SynG51D is hyper-phosphorylated at S129
and exacerbates mitochondrial fragmentation in
primary neurons
a-Syn phosphorylation at S129 has emerged as a pathological
hallmark of PD and other synucleinopathies (49). Therefore,
we sought to investigate whether the G51D mutation influences
a-Syn phosphorylation at S129. Strikingly, whereas no interplay
between S129 phosphorylation and the G51D mutation were
observed using in vitro kinase assays or in HEK cells upon
co-expression with two natural a-Syn kinases (PLK2 and
GRK6), experiments in primary neurons showed that the
a-SynG51D mutant exhibits much stronger nuclear phosphoryl-
ation by endogenous kinases compared to its WT counterpart.
This discrepancy could be due to masking effects in HEK cells
upon co-expression with kinases that efficiently phosphorylate
a-Syn, or due to intrinsic neuronal properties. Importantly, our
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results are in line with previous reports, suggesting that nuclear
a-Syn could be preferentially phosphorylated at S129 compared
to cytoplasmic a-Syn (47), and also with reports suggesting
enhanced phosphorylation of a-Syn PD mutants by
endogenous kinases in human brains as well as in transgenic
mice. In fact, detergent-insoluble a-Syn from PD brains
bearing the A53T mutation was shown to be hyper-
phosphorylated at S129 (95). Similarly, a-Syn inclusions from
transgenic mice brains expressing either the E46K or A53T
a-Syn mutants were also shown to have strong reactivity with
pS129 antibodies (96), although the A53T mutant was previous-
ly reported to have similar phosphorylation levels toa-SynWT in
SH-SY5Y cells (97), and slower in vitro phosphorylation
kinetics by casein kinase 2 (CK2) (98). Moreover, the fact that
transgenic mice expressing a-SynA53T showed strong nuclear
accumulation of total and S129 phosphorylated a-Syn, together
with the fact that we observe a similar effect with the novel G51D
mutant in primary neurons further suggests a potential role for
nuclear a-Syn in neuropathology (45,99). Finally, we investi-
gated whether the a-SynG51D has any toxic effects in neurons.
Although a-SynG51D expression was not toxic per se when
total numbers of neurons were assessed, it provoked more pro-
nounced mitochondrial fragmentation than a-SynWT, suggest-
ing that this mutant may be conferring toxic properties to
a-Syn in primary neuronal cells.
Summary and perspectives
In this study, we investigated the effect of the G51D mutation on
the biophysical and cellular properties of a-Syn using a wide
range of commonly used in vitro and cellular models. In vitro,
a-SynG51D exhibited attenuated aggregation and impaired
membrane binding. Both effects were recapitulated in yeast
cells but not in mammalian cell lines or primary neurons. In con-
trast, the G51D mutant showed enhanced secretion, nuclear
localization and phosphorylation in mammalian cells and
primary neurons, where it exacerbated a-Syn-induced mito-
chondrial fragmentation. Nevertheless, immunohistochemical
analysis of post-mortem human brain tissues of a-SynG51D
cases revealed only partial colocalization with nuclear mem-
brane markers. These findings suggest that effects of PD-linked
mutations could be context dependent, and that properties
of a-Syn variants should be investigated in different model
systems. Future studies should focus on investigating the
effects of this novel mutation further in vivo, by generating
transgenic animal models expressing this mutant, and compar-
ing side by side the toxicity, subcellular localization and
phosphorylation of both proteins.
MATERIALS AND METHODS
Plasmids and cloning
The pAAV-PGK humana-SynWT and the pT7-7 humana-SynWT
plasmids were kindly provided by the laboratories of Prof. Patrick
Aebisher, EPFL, Switzerland, and Prof. Peter Lansbury, Harvard
Medical School, USA, respectively. For the generation of the
pmEOS2–a-Syn fusionconstruct,humana-SyncDNAwas amp-
lified by polymerase chain reaction (PCR) and cloned into the
pmEOS2-C1 plasmid (minus the start codon) to generate the
mEOS2–a-Syn fusion. The G51D mutation was then introduced
into the pAAV-PGK a-Syn, pT7-7 a-Syn and mEOS2-a-Syn
plasmids using the QuikChange
w
site-directed mutagenesis
system (Stratagene). For yeast experiments, an a-Syn Gatewayw
entry clone was obtained from Invitrogen, containing full-length
human a-Syn in the vector pDONR221. To generate untagged
a-Syn constructs, this entry clone was used in a Gateway LR reac-
tion with pAG426GAL-ccdB to produce pAG426GALa-Syn.
To generate C-terminally YFP-tagged TDP-43 constructs, PCR
was performed to amplifya-Syn without a stop codon and incorp-
orateSpeI andHindIII restriction sites along with a Kozak consen-
sus sequence. The resulting PCR product was cloned into
SpeI/HindIII digested pRS426GAL-YFP to generate the 2m
a-Syn-YFP fusion construct. Each PD-linked mutant construct
was generatedbyusing the QuickChangew site-directed mutagen-
esis system (Stratagene) with pRS426GAL–a-Syn-YFP as
template. The pCDNA-CMV PLK2 and pCDNA-CMV GRK6
were kindly provided by the laboratories of Prof. Ingrid
Hoffman, German Cancer Research Center, Germany, and Prof.
Dario Diviani, UNIL, Switzerland, respectively. The plasmids
encoding the membrane, endoplasmic reticulum and mitochon-
drial fluorescent markers were obtained from BD Biosciences,
Clontech. All constructs were confirmed by DNA sequencing
(Microsynth) and agarose gel electrophoresis.
Protein expression and purification
BL21(DE3) cells transformed with pT7-7 plasmid encoding for
a-SynWT or a-SynG51D were grown in the LB medium at 378C,
and induced with 1 mM 1-thio-b-D-galactopyranoside (Appli-
Chem) for 4 h. Induced bacterial cultures were pelleted and
lysed by sonication. After centrifugation at 48 000g for 20 min,
the supernatant was boiled for 5 min and centrifuged again for
20 min. The supernatant was purified by anion-exchange
(HiPrep 16/10 Q FF, GE Healthcare Life Sciences), followed by
gel filtration (HiLoad 26/60 Superdex 200, GE Healthcare Life
Sciences), reverse phase C4 HPLC (Proto 300 C4, 20 mm
I.D. × 250 mm, 10 mm average bead diameter,Higgins Analytic-
al) and lyophilized. Isotopically labeled (15N and 15N,13C)
a-SynG51D was generated as previously reported (7). Specifically,
E. coliBL21 (DE3) cells expressing the a-SynG51D plasmid were
first grown in rich media, then transferred to minimal media con-
taining either 15N-labeled ammonium chloride or 15N-labeled
ammonium chloride and 13C-labeled glucose for production of
15N-labeled or 15N-, 13C-labeled protein, respectively, before in-
ductionwith IPTG(100).After3.5 hof induction at378C,bacteria
were lysed by sonication and the lysate was either directly used for
NMR experiments or subjected to further purification, consisting
of ammonium sulfate precipitation, anion-exchange chromatog-
raphy, reversed-phase HPLC and lyophilization.
NMR experiments
NMR experiments were carried out on Varian Inova or Bruker
Avance 600 or 800 MHz spectrometers equipped with cryogenic
probes. All data were collected at 108C, except for data from
samples containing SDS, which were collected at 408C. Purified
protein concentrations were 150 mM for lipid binding experi-
ments and 200 mM for SDS-binding experiments; protein
concentration in experiments employing cell lysates was
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estimated at 200 mM. Backbone amide assignments were trans-
ferred from previously published WT assignments (7,20) for
the free and SDS micelle-bound states of the protein using
HNCA experiments. The free state HNCA was collected using
fresh cell lysates with spectral widths of 12, 26 and 26 ppm
and 1024, 48 and 84 complex points in the 1H, 15N and 13C
dimensions, respectively. The SDS-bound HNCA was collected
on lyophilized purified protein dissolved in NMR buffer
(100 mM NaCl, 20 mM NaHPO4, pH 6.8) and mixed with SDS
stock to a final concentration of 40 mM SDS, 200 mM protein,
with spectral widths of 14, 28 and 26 ppm and 1024, 32 and 80
complex points in the 1H, 15N and 13C dimensions, respectively.
NMR data were processed with NMR-Pipe (101) and analyzed
with NMR ViewJ (102). The difference in the chemical shift
of each amide cross-peak between the a-SynG51Dand a-SynWT
spectra was calculated as Ddamide ¼ p(12(DdHN2 + (DdN/5)2)).
Secondary shifts were calculated as DdCa ¼ dCa,meas – dCa,RC,
using temperature- and neighbor-corrected random coil shifts
published by Kjaergaard and Poulsen (103). Lipid-binding was
assessed by comparing the bound population of a-SynG51D and
a-SynWT at a single concentration of lipid vesicles, as reported
by cross-peak intensities in matched 1H,15N-HSQC spectra of
lipid-free and lipid-containing (15% DOPS 25% DOPE 60%
DOPC SUVs) samples (23). SUVs were prepared as previously
reported, with slight modification, by mixing chloroform-
dissolved lipids, drying under nitrogen, resuspending in NMR
buffer, sonicating and clarifying by ultracentrifugation (20).
Purified lyophilized a-SynG51D was dissolved in NMR buffer
and mixed with SUV stock solutions to a final concentration of
3 mM lipid and 150 mM protein. PRE samples were prepared by
dissolving lyophilized protein containing the E20C mutation
(200 mM final concentration) in NMR buffer with a 10-fold
molar excess of the spin-label reagent S-(2,2,5,5-tetramethyl-
2,5-dihydro-1H-pyrrol-3-yl)methylmethanesulfonothioate
(MTSL), incubating for 1 h and removing excess spin-label
using Sephadex G-25 beads. The conjugated protein solution
was then split into two samples and DTT (2 mM) added to one,
in order to reduce the spin-label and generate a diamagnetic
control sample. Matched 1H,15N-HSQC spectra were then col-
lected on the paramagnetic and diamagnetic samples, and the
cross-peak intensity ratio taken to estimate the PRE effect in a
sequence-specific manner.
In vitro fibrillization and sedimentation assays
Lyophilized proteins were dissolved in 50 mM Tris and 150 mM
NaCl, pH 7.5 and filtered through a 100 kDa MW-cut-off filter.
Fibril formation was induced by incubating the protein (10 mM)
at 378C and pH 7.5 (50 mM Tris and 150 mM NaCl) under con-
stant agitation at 1000 rpm on an orbital shaker, for up to
120 h. Amyloid formation was monitored by Thioflavin T
(ThT) binding, soluble protein content, circular dichroism
(CD) and transmission electron microscopy (TEM). ThT fluor-
escence reading (excitation wavelength of 450 nm, emission
wavelength of 485 nm) was performed in triplicates with a
ThT concentration of 10 mM and a protein concentration of
1 mM in 50 mM glycine pH 8.5, using a Bucher Analyst AD
plate reader. To determine the remaining soluble protein
content, aliquots of samples at each time point were centrifuged
at 20 000g for 10 min at 48C to pellet insoluble aggregates, and
the supernatant was run on 15% SDS–PAGE, which was stained
with a Coomassie R-450 solution. The relative amounts of
soluble protein with respect to the initial conditions were deter-
mined by densitometry analysis (ImageJ).
Circular dichroism
CD was performed on a Jasco J-815 CD spectrometer at 208C.
CD spectra were acquired in the range of 195–250 nm using a
1.0 mm optical path length quartz cuvette. Data were collected
using the following parameters: data pitch, 0.2 nm; bandwidth,
1 nm; scanning speed, 50 nm/min; digital integration time, 2 s.
For each sample, five spectra were averaged and smoothed
using binomial approximation.
Transmission electron microscopy
3.5 ml of sample was applied onto glow-discharged Formvar/
carbon-coated 200-mesh copper grids (Electron Microscopy
Sciences) for 60 s. The grid was then blotted with filter paper,
washed twice with ultrapure water, once with staining solution
(Uranyl formate 0.7% w/V) and then stained for 30 s, blotted
off and dried by vacuum suction. Imaging was carried out on a
Tecnai Spirit BioTWIN electron microscope operated at 80 kV
and equipped with a LaB6 gun and a 4K × 4K FEI Eagle CCD
camera (FEI).
Lipid vesicle preparation
Phospholipids in chloroform (1-hexadecanoyl-2-(9Z-octadece-
noyl)-sn-glycero-3-phospho-(1′-rac-glycerol), (POPG) from
Avanti Polar Lipids, Inc. were dried using an argon stream to
form a thin film on the wall of a glass vial. Potential remaining
of chloroform was removed by placing the vial under vacuum
overnight. The phospholipids were then resolubilized to the
desired stock concentration by water bath sonication. The solu-
tion was then extruded through the Avestin LiposoFastTM
(Avestin Inc.), according to the manufacturer’s instructions.
Multi angle light scattering
Thirty micromolar 100 KDa cut-off filtered samples were
applied onto a Superdex 200 10/300 GL (GE Healthcare Life
Sciences), on an Agilent technologies series 1200 instruments
(Agilent Technologies, Inc., Santa Clara, CA, UA) coupled to
a refractive index detection (OptilabrEX, Wyatt Technology
Corporation) and eight-angles light scattering detectors
(DAWN 8+, Wyatt Technology Corporation). Molecular
weight determination was performed using the Astra 5.3 analysis
software (Wyatt Technology Corporation).
Yeast strains, media, transformation, spotting and imaging
Yeast cells were grown in rich media (YPD) or in synthetic
media lacking uracil and containing 2% glucose (SD/-Ura), raf-
finose (SRaf/-Ura) or galactose (SGal/-Ura). 2 m plasmid con-
structs (e.g. pRS416GALa-Syn-YFP) were transformed into
BY4741 (MATa his3 leu2 met15 ura3) according to standard
protocols. We used the PEG/lithium acetate method to transform
yeast with plasmid DNA. For spotting assays, yeast cells were
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grown overnight at 308C in liquid media containing SRaf/-Ura
until they reached log or mid-log phase. Cultures were then nor-
malized for OD600, serially diluted and spotted with a Frogger
(V&P Scientific) onto synthetic solid media containing
glucose (SD/-Ura) or galactose (SGal/-Ura) lacking uracil and
were grown at 308C for 2–3 days. For fluorescence microscopy
experiments, single colony isolates of the yeast strains were
grown to mid-log phase in SRaf/-Ura media at 308C. Cultures
were spun down and resuspended in the same volume of
SGal/-Ura to induce expression of the a-Syn-YFP constructs
for 6 h before being processed for microscopy.
HEK293T cell culture and transfection
HEK293T cells were grown at 378C, with 5% CO2 in Dulbecco’s
modified Eagle’s medium (DMEM, GIBCO) supplemented with
10% fetal bovine serum (FBS, GIBCO) and 1% penicillin/strep-
tomycin (Sigma-Aldrich). Cells were then plated on cover slips
(12 mm, Milian) which had been precoated with poly-L-lysine
(Sigma-Aldrich) for immunocytochemistry, in six-well plates
for biochemistry, or in 35 mm fluorodishes (World Precision)
for live imaging experiments, and then transfected with appro-
priate plasmids using the standard calcium phosphate (CaPO4)
transfection method. Cells were maintained at 378C and ana-
lyzed 24 h post transfection.
HEK293T protein extraction and western blotting
Cells were harvested and lysed with 80 ml lysis buffer/well
(20 mM Trizma base, 150 mM NaCl, 1 mM EDTA, 0.25%
Nonidet P-40, 0.25% Triton-X, pH 7.4) supplemented with
1 mM PMSF (Sigma) and 1:100 protease inhibitor cocktail
(Sigma). The lysates were vortexed and then kept on ice for
30 min before being centrifuged at 20 817g for 15 min at 48C.
The total protein amount in the supernatant (Triton-soluble)
was determined using the BCATM protein assay kit (Pierce)
according to the manufacturer’s instructions. Equal protein
amounts were then separated on 16% SDS 1.5 mm gels and
transferred to a nitrocellulose membrane using a semi-dry trans-
fer cell from Bio-Rad. The membrane was then blocked for 1 h at
RT with Odyssey blocking buffer (Li-COR Biosciences GmbH)
diluted 1:3 in PBS, and probed with primary antibodies (Supple-
mentary Material, Table S1) at 48C overnight. After three
washes in PBST [PBS 0.01% (v/v) Tween-20 (Fluka)], the mem-
brane was incubated with Alexa Fluor (680 or 800 nm) conju-
gated secondary antibodies (Invitrogen; Carlsbad, CA;
Li-COR Biosciences GmbH) at RT for 1 h, washed three times
with PBST and scanned using a Li-COR scanner at a wavelength
of 700 or 800 nm.
Subcellular fractionation of HEK293T cells
The fractionation of HEK293T cells was carried out employing
the subcellular proteome extraction kit (Calbiochem Cat.
539790) according to the manufacturer’s instructions. The frac-
tions were analyzed by western blotting, and their purity was
established using control antibodies against markers of subcellu-
lar compartments provided by the kit (Hsp90 for cytosol and
Parp-1 for the nuclear fraction) at 1:1000 dilution in blocking
buffer.
Maintenance of differentiated SH-SY5Y cell lines
and transfection
SH-SY5Y cells were cultured and differentiated as described
previously (65). Briefly, cells were cultured in 10 mm dishes
and differentiated with 10 ml of DMEM supplemented with
10% FBS, 1% Pen/Strep and 50 mM Retinoic Acid (RA) in a
humidified incubator at 378C. To maintain the cells in differen-
tiated conditions, the growth media was renewed every 2 days
until the day of experiment. Cells were then electroporated
with 10 mg of DNA and kept at 378C for 48 h to allow optimal
expression of the transgene.
Preparation of CM from SH-SY5Y cells
At 48 h post transfection, cells were washed two times with pre-
warmed DMEM and incubated for 18 h with fresh DMEM
without FBS. The culture supernatant was collected and centri-
fuged at 1000g for 10 min at 48C to pellet cellular debris. The
supernatant was centrifuged again at 10 000g for 15 min at
48C, and the conditioned medium was collected and analyzed
by western blot. To obtain cellular lysates, cells were harvested
and lysed in lysis buffer [1% Triton X-100 in cold PBS supple-
mented with protease inhibitor cocktail (Sigma)]. After a
10 min incubation on ice, the cell lysate was centrifuged at
16 000g for 10 min at 48C, and the supernatant (Triton-soluble
fraction) was collected in a new clean tube. The concentrations
of the samples were determined by BCATM (Pierce) protein
assay kit, and equal amounts of proteins per sample were
resolved in 12% polyacrylamide gel electrophoresis and pro-
ceeded for western blot.
Primary neuron culture preparation and transfection
Primary hippocampal neuronal cultures were prepared from P0
WT mice (Harlan Laboratories, Netherlands) as previously
described (104). Briefly, hippocampi were dissociated with
papain and triturated using a glass pipette. After centrifugation
at 400g for 2 min, cells were plated in MEM/10% FCS onto
poly-L-lysine (BD Biosciences) coated cover slips (12 mm,
VWR) at 1.5 × 105 cells/ml. Medium was changed after 4 h to
Neurobasal/B27 medium, and neurons were treated with
ARAC (Sigma) after 6 days to stop glial division. After 7 days
in vitro (DIV), neurons were transiently transfected with
0.5 mg of plasmid using LipofectamineTM 2000 (Invitrogen)
according to the manufacturer’s instructions, and analyzed
48 h later.
Immunocytochemistry
HEK cells or primary neurons were washed with PBS, fixed with
4% paraformaldehyde in PBS and then incubated in blocking
buffer [3% bovine serum albumin (BSA), 0.02% Saponin in
PBS] for 1 h at RT. Then, cover slips were incubated overnight
at 48C in blocking buffer comprising primary antibodies (Sup-
plementary Material, Table S1). Subsequently, cover slips
were washed three times with PBS and incubated in blocking
buffer comprising appropriate Alexa Fluor conjugated second-
ary antibodies (Invitrogen) as well as the nuclear stain
4,6-diamidino-2-phenylindole (DAPI, 1:5000) for 1 h at RT.
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After three washes with PBS, cover slips were washed once with
double distilled water and then mounted on glass slides with
DABCO mounting medium (Sigma-Aldrich). Stained samples
were then imaged using the LSM700 point scanning confocal
microscope (Carl Zeiss).
Live imaging photoconversion experiments
Photoconversion was performed using the LSM 700 inverted
point scanning confocal microscope (Carl Zeiss) equipped
with an incubated stage maintained at 378C, using a
Plan-Apochromat 40×/1.3 Oil DIC M27 objective. Transfected
cells were first identified using a 488 nm laser (2% transmission)
and a 515–565 nm band pass filter to detect unconverted
mEOS2. Then, a circular region of interest (ROI, r ¼ 1 mm)
was photoconverted using a diode laser at 405 nm (20% trans-
mission) in the cytoplasm. Photoconverted mEOS2 was detected
upon excitation with a 555 nm diode laser, and then around 70
images (frame size 512 × 512, 0.06 × 0.06 mm, 8 bit, pixel
time: 0.64 ms) were acquired with an interval of around 4 s
with the pinhole set to 1 Airy unit for each cell. Photoconversion
was performed after the second image and was repeated after
every image acquisition. Around 25 neurons per condition
were analyzed. Time-lapse series of images showing mEOS2
fluorescent intensities were analyzed to measure photoconverted
mEOS2 intensities over time in the nucleus using the LSM Zen
2012 (blue edition) software.
LDH and Sytox green cytotoxicity assays
To assess the membrane integrity in SH-SY5Y cells, LDH cyto-
toxicity assay was performed on cell culture media using the
LDH cytotoxicity kit (Takara BIO INC, cat: MK401) as per man-
ufacturer’s instructions. Briefly, 20 ml of crude CM was diluted
5-fold in PBS and incubated for 30 min at RT with equal amounts
of catalyst solution (Diaphorase/NAD+) in the dark. The
enzymatic reaction was quenched with 2N HCl and absorbance
was immediately quantified at 490 nm. To assess the membrane
integrity in neurons, the Sytox green dye exclusion assay
was performed using Sytox green reagent (Molecular probes,
Invitrogen) as per manufacturer’s instructions. Briefly, Sytox
green dye was diluted (1:5000) in media of neurons plated and
transfected in 96-well clear bottom black plates (Corning, Cat:
3603), and then incubated for 30 min at 378C in the dark.
Neurons were subsequently washed twice with PBS, and then
fluorescence intensity per well was measured after adding
100 ml of PBS per well using the Infinite M200-Pro plate
reader (Excitation: 487 nm; Emission: 519 nm). Neurons were
then fixed and immunocytochemistry was performed as
described above.
Analysis of post-mortem human brains
Brain tissue was donated to the Queen Square Brain Bank for
Neurological Disorders, UCL Institute of Neurology using eth-
ically approved protocols and stored for research under a
license issued by the human Tissue Authority (No. 12198). Fol-
lowing division in the saggital plane, one half of each brain was
sliced in the coronal plane and immediately flash frozen and
stored at 2808C. Following fixation in 10% buffered formalin,
the remaining half brain was sliced in the coronal plane, exam-
ined and blocks were selected for paraffin wax embedding and
histology. Three G51D SNCA mutation cases were used in this
investigation, and the presence of the point mutation had been
confirmed by Sanger sequencing for exon 3 of SNCA. Paraffin
embedded sections (8 mm thick) were stained using primary
antibodies: a-Syn (Abcam, UK), Lamin A/C and Lamin B
(Santa Cruz Biotechnologies, CA, USA). Double immunofluor-
escence was detected using isotype specific anti-rabbit IgG or
anti-mouse IgG secondary antibodies conjugated with either
Alexa 488 or 594 fluorescent dyes (1:400) (Life technologies)
followed by quenching of auto-fluorescence with 0.1% Sudan
Black/70% Ethanol (Sigma-Aldrich) solution for 10 min and
mounting with glass cover slips using VECTA-shield mounting
media with DAPI nuclear stain (Vector laboratories). Images
were taken using fluorescence microscopy (Leica DM5500 B).
In order to determine the conformational state of a-SynG51D,
paraffin embedded (8 mm thick) sections from frontal lobe and
hippocampal regions were prepared for double staining with
a-Syn and Thioflavin S. Sections were pre-treated using 70%
formic acid anda-Syn was incubated overnight followed by bio-
tinylated anti-rabbit antibody, and finally ABC reagent. Sections
were finally counterstained in aqueous Thioflavin S.
SUPPLEMENTARY MATERIAL
Supplementary Material is available at HMG online.
ACKNOWLEDGEMENTS
We would like to thank Nathalie Jordan, John Perrin, Celine
Vocat and Trudy Ramlall for their excellent technical expertise,
and Prof. Virginia Lee for kindly providing the Syn-208
antibody.
Conflict of interest Statement. None declared.
FUNDING
This work was supported by researchers at the National Institute
for Health Research University College London Hospitals Bio-
medical Research Centre; by the Swiss Federal Institute of Tech-
nology and Swiss National Science Foundation (H.L.); National
Institutes of Health (R37AG019391 to D.E.); NYSTAR and
ORIP/NIH facility improvement grant (CO6RR015495 to
D.E.); a gift from Herbert and Ann Siegel (D.E.); the Reta Lila
Weston Institute for Neurological Studies (J.H.) and the Multiple
System Atrophy Trust (J.H., A.K.).
REFERENCES
1. Goedert, M., Spillantini, M.G., Del Tredici, K. and Braak, H. (2013) 100
years of Lewy pathology. Nat. Rev. Neurol., 9, 13–24.
2. Polymeropoulos, M.H., Lavedan, C., Leroy, E., Ide, S.E., Dehejia, A.,
Dutra, A., Pike, B., Root, H., Rubenstein, J., Boyer, R. et al. (1997)
Mutation in the alpha-synuclein gene identified in families with
Parkinson’s disease. Science, 276, 2045–2047.
3. Baba, M., Nakajo, S., Tu, P.H., Tomita, T., Nakaya, K., Lee, V.M.,
Trojanowski, J.Q. and Iwatsubo, T. (1998) Aggregation of alpha-synuclein
in Lewy bodies of sporadic Parkinson’s disease and dementia with Lewy
bodies. Am. J. Pathol., 152, 879–884.
4506 Human Molecular Genetics, 2014, Vol. 23, No. 17
4. Lashuel, H.A., Overk, C.R., Oueslati, A. and Masliah, E. (2013) The many
faces of alpha-synuclein: from structure and toxicity to therapeutic target.
Nat. Rev. Neurosci., 14, 38–48.
5. Bendor, J.T., Logan, T.P. and Edwards, R.H. (2013) The function of alpha-
synuclein. Neuron, 79, 1044–1066.
6. Weinreb, P.H., Zhen, W., Poon, A.W., Conway, K.A. and Lansbury, P.T. Jr.
(1996) NACP, a protein implicated in Alzheimer’s disease and learning, is
natively unfolded. Biochemistry, 35, 13709–13715.
7. Eliezer,D.,Kutluay,E.,Bussell,R. Jr. andBrowne,G. (2001)Conformational
properties of alpha-synuclein in its free and lipid-associated states. J. Mol.
Biol., 307, 1061–1073.
8. Davidson, W.S., Jonas, A., Clayton, D.F. and George, J.M. (1998)
Stabilization of alpha-synuclein secondary structure upon binding to
synthetic membranes. J. Biol. Chem., 273, 9443–9449.
9. Ahn, K.J., Paik, S.R., Chung, K.C. and Kim, J. (2006) Amino acid sequence
motifs and mechanistic features of the membrane translocation of
alpha-synuclein. J. Neurochem., 97, 265–279.
10. Ulmer, T.S., Bax, A., Cole, N.B. and Nussbaum, R.L. (2005) Structure and
dynamics of micelle-bound human alpha-synuclein. J. Biol. Chem., 280,
9595–9603.
11. Lansbury, P.T. Jr., Costa, P.R., Griffiths, J.M., Simon, E.J., Auger, M.,
Halverson, K.J., Kocisko, D.A., Hendsch, Z.S., Ashburn, T.T., Spencer,
R.G. et al. (1995) Structural model for the beta-amyloid fibril based on
interstrand alignment of an antiparallel-sheet comprising a C-terminal
peptide. Nat. Struct. Biol., 2, 990–998.
12. Singleton, A.B., Farrer, M., Johnson, J., Singleton, A., Hague, S.,
Kachergus, J., Hulihan, M., Peuralinna, T., Dutra, A., Nussbaum, R. et al.
(2003) alpha-Synuclein locus triplication causes Parkinson’s disease.
Science, 302, 841.
13. Chartier-Harlin, M.C., Kachergus, J., Roumier, C., Mouroux, V., Douay,
X., Lincoln, S., Levecque, C., Larvor, L., Andrieux, J., Hulihan, M. et al.
(2004) Alpha-synuclein locus duplicationas a cause of familial Parkinson’s
disease. Lancet, 364, 1167–1169.
14. Kruger, R., Kuhn, W., Muller, T., Woitalla, D., Graeber, M., Kosel, S.,
Przuntek, H., Epplen, J.T., Schols, L. and Riess, O. (1998) Ala30Pro
mutation in the gene encoding alpha-synuclein in Parkinson’s disease.Nat.
Genet., 18, 106–108.
15. Zarranz, J.J., Alegre, J., Gomez-Esteban, J.C., Lezcano, E., Ros, R.,
Ampuero, I., Vidal, L., Hoenicka, J., Rodriguez, O., Atares, B. et al. (2004)
The new mutation, E46 K, of alpha-synuclein causes Parkinson and Lewy
body dementia. Ann. Neurol., 55, 164–173.
16. Appel-Cresswell, S., Vilarino-Guell, C., Encarnacion, M., Sherman, H.,
Yu, I., Shah, B., Weir, D., Thompson, C., Szu-Tu, C., Trinh, J. et al. (2013)
Alpha-synuclein p.H50Q, a novel pathogenic mutation for Parkinson’s
disease. Mov. Disord., 28, 811–813.
17. Kiely, A.P., Asi, Y.T., Kara, E., Limousin, P., Ling, H., Lewis, P.,
Proukakis, C., Quinn, N., Lees, A.J., Hardy, J. et al. (2013)
alpha-Synucleinopathy associated with G51D SNCA mutation: a link
between Parkinson’s disease and multiple system atrophy? Acta
Neuropathol., 125, 753–769.
18. Lesage, S., Anheim, M., Letournel, F., Bousset, L., Honore, A., Rozas, N.,
Pieri, L., Madiona, K., Durr, A., Melki, R. et al. (2013) G51D
alpha-synuclein mutation causes a novel parkinsonian-pyramidal
syndrome. Ann. Neurol., 73, 459–471.
19. Ghosh, D., Mondal, M., Mohite, G.M., Singh, P.K., Ranjan, P., Anoop, A.,
Ghosh, S., Jha, N.N., Kumar, A. and Maji, S.K. (2013) The Parkinson’s
disease-associated H50Q mutation accelerates alpha-Synuclein
aggregation in vitro. Biochemistry, 52, 6925–6927.
20. Bussell, R. Jr. and Eliezer, D. (2003) A structural and functional role for
11-mer repeats in alpha-synuclein and other exchangeable lipid binding
proteins. J. Mol. Biol., 329, 763–778.
21. Chandra, S., Chen, X., Rizo, J., Jahn, R. and Sudhof, T.C. (2003) A broken
alpha -helix in folded alpha-Synuclein. J. Biol. Chem., 278, 15313–15318.
22. Borbat, P., Ramlall, T.F., Freed, J.H. and Eliezer, D. (2006) Inter-helix
distances in lysophospholipid micelle-bound alpha-synuclein from pulsed
ESR measurements. J. Am. Chem. Soc., 128, 10004–10005.
23. Bussell, R. Jr. and Eliezer, D. (2004) Effects of Parkinson’s disease-linked
mutations on the structure of lipid-associated alpha-synuclein.
Biochemistry, 43, 4810–4818.
24. Bodner, C.R., Dobson, C.M. and Bax, A. (2009) Multiple tight
phospholipid-binding modes of alpha-synuclein revealed by solution NMR
spectroscopy. J. Mol. Biol., 390, 775–790.
25. Rizo, J., Blanco, F.J., Kobe, B., Bruch, M.D. and Gierasch, L.M. (1993)
Conformational behavior of Escherichia coli OmpA signal peptides in
membrane mimetic environments. Biochemistry, 32, 4881–4894.
26. Bodner, C.R., Maltsev, A.S., Dobson, C.M. and Bax, A. (2010) Differential
phospholipid binding of alpha-synuclein variants implicated in Parkinson’s
disease revealed by solution NMR spectroscopy. Biochemistry, 49,
862–871.
27. Drescher,M., Godschalk,F., Veldhuis, G., van Rooijen, B.D., Subramaniam,
V. and Huber, M. (2008) Spin-label EPR on alpha-synuclein reveals
differences in the membrane binding affinity of the two antiparallel helices.
Chembiochem, 9, 2411–2416.
28. Bartels, T., Ahlstrom, L.S., Leftin, A., Kamp, F., Haass, C., Brown, M.F.
and Beyer, K. (2010) The N-terminus of the intrinsically disordered protein
alpha-synuclein triggers membrane binding and helix folding. Biophys. J.,
99, 2116–2124.
29. Anderson, V.L., Ramlall, T.F., Rospigliosi, C.C., Webb, W.W. and Eliezer,
D. (2010) Identification of a helical intermediate in trifluoroethanol-
induced alpha-synuclein aggregation. Proc. Natl Acad. Sci. USA, 107,
18850–18855.
30. Uversky, V.N., Li, J. and Fink, A.L. (2001) Evidence for a partially folded
intermediate in alpha-synuclein fibril formation. J. Biol. Chem., 276,
10737–10744.
31. Outeiro, T.F. and Lindquist, S. (2003) Yeast cells provide insight into
alpha-synuclein biology and pathobiology. Science, 302, 1772–1775.
32. Willingham, S., Outeiro, T.F., DeVit, M.J., Lindquist, S.L. and
Muchowski, P.J. (2003) Yeast genes that enhance the toxicity of a mutant
huntingtin fragment or alpha-synuclein. Science, 302, 1769–1772.
33. Cooper, A.A., Gitler, A.D., Cashikar, A., Haynes, C.M., Hill, K.J., Bhullar,
B., Liu, K., Xu, K., Strathearn, K.E., Liu, F. et al. (2006) Alpha-synuclein
blocks ER-Golgi traffic and Rab1 rescues neuron loss in Parkinson’s
models. Science, 313, 324–328.
34. Gitler, A.D., Bevis, B.J., Shorter, J., Strathearn, K.E., Hamamichi, S., Su,
L.J., Caldwell, K.A., Caldwell, G.A., Rochet, J.C., McCaffery, J.M. et al.
(2008) The Parkinson’s disease protein alpha-synuclein disrupts cellular
Rab homeostasis. Proc. Natl Acad. Sci. USA, 105, 145–150.
35. Gitler, A.D., Chesi, A., Geddie, M.L., Strathearn, K.E., Hamamichi, S.,
Hill, K.J., Caldwell, K.A., Caldwell, G.A., Cooper, A.A., Rochet, J.C. et al.
(2009) Alpha-synuclein is part of a diverse and highly conserved
interaction network that includes PARK9 and manganese toxicity. Nat.
Genet., 41, 308–315.
36. Yeger-Lotem, E., Riva, L., Su, L.J., Gitler, A.D., Cashikar, A.G., King,
O.D., Auluck, P.K., Geddie, M.L., Valastyan, J.S., Karger, D.R. et al.
(2009) Bridging high-throughput genetic and transcriptional data reveals
cellular responses to alpha-synuclein toxicity. Nat. Genet., 41, 316–323.
37. Tardiff, D.F., Jui, N.T., Khurana, V., Tambe, M.A., Thompson, M.L.,
Chung,C.Y., Kamadurai, H.B., Kim,H.T., Lancaster, A.K.,Caldwell, K.A.
et al. (2013) Yeast reveal a "druggable" Rsp5/Nedd4 network that
ameliorates alpha-synuclein toxicity in neurons. Sciencei, 342, 979–983.
38. Bussell, R. Jr. and Eliezer, D. (2001) Residual structure and dynamics in
Parkinson’s disease-associated mutants of alpha-synuclein. J. Biol. Chem.,
276, 45996–46003.
39. Cole, N.B., Murphy, D.D., Grider, T., Rueter, S., Brasaemle, D. and
Nussbaum, R.L. (2002) Lipid droplet binding and oligomerization
properties of the Parkinson’s disease protein alpha-synuclein. J. Biol.
Chem., 277, 6344–6352.
40. Jensen, P.H., Nielsen, M.S., Jakes, R., Dotti, C.G. and Goedert, M. (1998)
Binding of alpha-synuclein to brain vesicles is abolished by familial
Parkinson’s disease mutation. J. Biol. Chem., 273, 26292–26294.
41. McKinney, S.A., Murphy, C.S., Hazelwood, K.L., Davidson, M.W. and
Looger, L.L. (2009) A bright and photostable photoconvertible fluorescent
protein. Nat. Methods, 6, 131–133.
42. Specht, C.G., Tigaret, C.M., Rast, G.F., Thalhammer, A., Rudhard, Y. and
Schoepfer, R. (2005) Subcellular localisation of recombinant alpha- and
gamma-synuclein. Mol. Cell. Neurosci., 28, 326–334.
43. Ma, K.L., Song, L.K., Yuan, Y.H., Zhang, Y., Han, N., Gao, K. and Chen,
N.H. (2013) The nuclear accumulation of alpha-synuclein is mediated by
importin alpha and promotes neurotoxicity by accelerating the cell cycle.
Neuropharmacology. http://dx.doi.org/10.1016/j.neuropharm.2013.07.035.
44. Goncalves, S. and Outeiro, T.F. (2013) Assessing the subcellular dynamics
of alpha-synuclein using photoactivation microscopy.Mol. Neurobiol., 47,
1081–1092.
Human Molecular Genetics, 2014, Vol. 23, No. 17 4507
45. Schell, H., Hasegawa, T., Neumann, M. and Kahle, P.J. (2009) Nuclear and
neuritic distribution of serine-129 phosphorylated alpha-synuclein in
transgenic mice. Neuroscience, 160, 796–804.
46. Mbefo, M.K., Paleologou, K.E., Boucharaba, A., Oueslati, A., Schell, H.,
Fournier, M., Olschewski, D., Yin, G., Zweckstetter, M., Masliah, E. et al.
(2010) Phosphorylation of synucleins by members of the Polo-like kinase
family. J. Biol. Chem., 285, 2807–2822.
47. Wakamatsu, M., Ishii, A., Ukai, Y., Sakagami, J., Iwata, S., Ono, M.,
Matsumoto, K., Nakamura, A., Tada, N., Kobayashi, K. et al. (2007)
Accumulation of phosphorylated alpha-synuclein in dopaminergic neurons
of transgenic mice that express human alpha-synuclein. J. Neurosci. Res.,
85, 1819–1825.
48. Huang, Z., Xu, Z., Wu, Y. and Zhou, Y. (2011) Determining nuclear
localization of alpha-synuclein in mouse brains. Neuroscience, 199,
318–332.
49. Oueslati, A., Fournier, M. and Lashuel, H.A. (2010) Role of
post-translational modifications in modulating the structure, function and
toxicity of alpha-synuclein: implications for Parkinson’s disease
pathogenesis and therapies. Prog. Brain Res., 183, 115–145.
50. Sato, H., Arawaka, S., Hara, S., Fukushima, S., Koga, K., Koyama, S. and
Kato, T. (2011) Authentically phosphorylated alpha-synuclein at Ser129
accelerates neurodegeneration in a rat model of familial Parkinson’s
disease. J. Neurosci., 31, 16884–16894.
51. Oueslati, A., Schneider, B.L., Aebischer, P. and Lashuel, H.A. (2013)
Polo-like kinase 2 regulates selective autophagic alpha-synuclein
clearance and suppresses its toxicity in vivo. Proc. Natl Acad. Sci. USA,
110, E3945–E3954.
52. Esteves, A.R., Arduino, D.M., Silva, D.F., Oliveira, C.R. and Cardoso,
S.M. (2011) Mitochondrial dysfunction: the road to alpha-Synuclein
oligomerization in PD. Parkinsons Dis., 2011, 693761.
53. Lee, S.J. (2003) alpha-synuclein aggregation: a link between mitochondrial
defects and Parkinson’s disease? Antioxid Redox Signal, 5, 337–348.
54. Ko, L.W., Ko, H.H., Lin, W.L., Kulathingal, J.G. and Yen, S.H. (2008)
Aggregates assembled from overexpression of wild-type alpha-synuclein
are not toxic to human neuronal cells. J. Neuropathol. Exp. Neurol., 67,
1084–1096.
55. Cookson, M.R. (2009) alpha-Synuclein and neuronal cell death. Mol.
Neurodegener., 4, 9.
56. El-Agnaf, O.M., Salem, S.A., Paleologou, K.E., Cooper, L.J., Fullwood,
N.J., Gibson, M.J., Curran, M.D., Court, J.A., Mann, D.M., Ikeda, S. et al.
(2003) Alpha-synuclein implicated in Parkinson’s disease is present in
extracellular biological fluids, including human plasma. FASEB J., 17,
1945–1947.
57. Borghi, R., Marchese, R., Negro,A., Marinelli, L., Forloni, G., Zaccheo, D.,
Abbruzzese, G. and Tabaton, M. (2000) Full length alpha-synuclein is
present in cerebrospinal fluid from Parkinson’s disease and normal
subjects. Neurosci. Lett., 287, 65–67.
58. Fjorback, A.W., Varming, K. and Jensen, P.H. (2007) Determination of
alpha-synuclein concentration in human plasma using ELISA. Scand. J.
Clin. Lab. Invest., 67, 431–435.
59. Kasuga, K., Nishizawa, M. and Ikeuchi, T. (2012) alpha-Synuclein as CSF
and blood biomarker of dementia with Lewy bodies. Int. J. Alzheimer Dis.,
2012, 437025.
60. Tinsley, R.B., Kotschet, K., Modesto, D., Ng, H., Wang, Y., Nagley, P.,
Shaw, G. and Horne, M.K. (2010) Sensitive and specific detection of
alpha-synuclein in human plasma. J. Neurosci. Res., 88, 2693–2700.
61. Devic, I., Hwang, H., Edgar, J.S., Izutsu, K., Presland, R., Pan, C., Goodlett,
D.R., Wang, Y., Armaly, J., Tumas, V. et al. (2011) Salivary
alpha-synuclein and DJ-1: potential biomarkers for Parkinson’s disease.
Brain, 134, e178.
62. Cersosimo, M.G., Perandones, C., Micheli, F.E., Raina, G.B., Beron, A.M.,
Nasswetter, G., Radrizzani, M. and Benarroch, E.E. (2011)
Alpha-synuclein immunoreactivity in minor salivary gland biopsies of
Parkinson’s disease patients. Mov. Disord., 26, 188–190.
63. Desplats, P., Lee, H.J., Bae, E.J., Patrick, C., Rockenstein, E., Crews, L.,
Spencer, B., Masliah, E. and Lee, S.J. (2009) Inclusion formation and
neuronal cell death through neuron-to-neuron transmission of
alpha-synuclein. Proc. Natl Acad. Sci. USA, 106, 13010–13015.
64. Emmanouilidou, E., Stefanis, L. and Vekrellis, K. (2010) Cell-produced
alpha-synuclein oligomers are targeted to, and impair, the 26S proteasome.
Neurobiol. Aging, 31, 953–968.
65. Lee, H.J., Patel, S. and Lee, S.J. (2005) Intravesicular localization
and exocytosis of alpha-synuclein and its aggregates. J. Neurosci., 25,
6016–6024.
66. Lee, H.J., Suk, J.E., Bae, E.J. and Lee, S.J. (2008) Clearance and deposition
of extracellular alpha-synuclein aggregates in microglia. Biochem.
Biophys. Res. Commun., 372, 423–428.
67. Li, J., Uversky, V.N. and Fink, A.L. (2001) Effect of familial Parkinson’s
disease point mutations A30P and A53 T on the structural properties,
aggregation, and fibrillation of human alpha-synuclein. Biochemistry, 40,
11604–11613.
68. Giasson, B.I., Uryu, K., Trojanowski, J.Q. and Lee, V.M. (1999) Mutant
and wild type human alpha-synucleins assemble into elongated filaments
with distinct morphologies in vitro. J. Biol. Chem., 274, 7619–7622.
69. Conway, K.A., Lee, S.J., Rochet, J.C., Ding, T.T., Williamson, R.E. and
Lansbury, P.T. Jr. (2000) Acceleration of oligomerization, not
fibrillization, is a shared property of both alpha-synuclein mutations linked
to early-onset Parkinson’s disease: implications for pathogenesis and
therapy. Proc. Natl Acad. Sci. USA, 97, 571–576.
70. Georgieva, E.R., Ramlall, T.F., Borbat, P.P., Freed, J.H. and Eliezer, D.
(2008) Membrane-bound alpha-synuclein forms an extended helix:
long-distance pulsed ESR measurements using vesicles, bicelles, and
rodlike micelles. J. Am. Chem. Soc., 130, 12856–12857.
71. Jao, C.C., Hegde, B.G., Chen, J., Haworth, I.S. and Langen, R. (2008)
Structure of membrane-bound alpha-synuclein from site-directed spin
labeling and computational refinement. Proc. Natl Acad. Sci. USA, 105,
19666–19671.
72. Dikiy, I. and Eliezer, D. (2012) Folding and misfolding of alpha-synuclein
on membranes. Biochim. Biophys. Acta, 1818, 1013–1018.
73. Georgieva, E.R., Ramlall, T.F., Borbat, P.P., Freed, J.H. and Eliezer, D.
(2010) The lipid-binding domain of wild type and mutant alpha-synuclein:
compactness and interconversion between the broken and extended helix
forms. J. Biol. Chem., 285, 28261–28274.
74. Asi, Y.T., Simpson, J.E., Heath, P.R., Wharton, S.B., Lees, A.J., Revesz, T.,
Houlden, H. and Holton, J.L. (2014) Alpha-synuclein mRNA expression in
oligodendrocytes in MSA. Glia., 62, 964–970.
75. Reyes, J.F., Rey, N.L., Bousset, L., Melki, R., Brundin, P. and Angot, E.
(2014) Alpha-synuclein transfers from neurons to oligodendrocytes. Glia,
62, 387–398.
76. Maroteaux, L., Campanelli, J.T. and Scheller, R.H. (1988) Synuclein: a
neuron-specific protein localized to the nucleus and presynaptic nerve
terminal. J. Neurosci., 8, 2804–2815.
77. Abeliovich, A., Schmitz, Y., Farinas, I., Choi-Lundberg, D., Ho, W.H.,
Castillo, P.E., Shinsky, N., Verdugo, J.M., Armanini, M., Ryan, A. et al.
(2000) Mice lacking alpha-synuclein display functional deficits in the
nigrostriatal dopamine system. Neuron, 25, 239–252.
78. Chandra, S., Gallardo, G., Fernandez-Chacon, R., Schluter, O.M. and
Sudhof, T.C. (2005) Alpha-synuclein cooperates with CSPalpha in
preventing neurodegeneration. Cell, 123, 383–396.
79. Totterdell, S. and Meredith, G.E. (2005) Localization of alpha-synuclein to
identified fibers and synapses in the normal mouse brain. Neuroscience,
135, 907–913.
80. Lee, S.J., Jeon, H. and Kandror, K.V. (2008) Alpha-synuclein is localized in
a subpopulation of rat brain synaptic vesicles. Acta. Neurobiol. Exp.
(Wars), 68, 509–515.
81. Watson, J.B., Hatami, A., David, H., Masliah, E., Roberts, K., Evans, C.E.
and Levine, M.S. (2009) Alterations in corticostriatal synaptic plasticity
in mice overexpressing human alpha-synuclein. Neuroscience, 159,
501–513.
82. Yu, S., Li, X., Liu, G., Han, J., Zhang, C., Li, Y., Xu, S., Liu, C., Gao, Y.,
Yang, H. et al. (2007) Extensive nuclear localization of alpha-synuclein in
normal rat brain neurons revealed by a novel monoclonal antibody.
Neuroscience, 145, 539–555.
83. Zhang, L., Zhang, C., Zhu, Y., Cai, Q., Chan, P., Ueda, K., Yu, S. and Yang,
H. (2008) Semi-quantitative analysis of alpha-synuclein in subcellular
pools of rat brain neurons: an immunogold electron microscopic study
using a C-terminal specific monoclonal antibody.BrainRes., 1244, 40–52.
84. Vivacqua, G., Yin, J.J., Casini, A., Li, X., Li, Y.H., D’Este, L., Chan, P.,
Renda, T.G. and Yu, S. (2009) Immunolocalization of alpha-synuclein in
the rat spinal cord by two novel monoclonal antibodies.Neuroscience, 158,
1478–1487.
85. Zhong, S.C., Luo, X., Chen, X.S., Cai, Q.Y., Liu, J., Chen, X.H. and Yao,
Z.X. (2010) Expression and subcellular location of alpha-synuclein during
mouse-embryonic development. Cell Mol. Neurobiol., 30, 469–482.
4508 Human Molecular Genetics, 2014, Vol. 23, No. 17
86. Xu, S., Zhou, M., Yu, S., Cai, Y., Zhang, A., Ueda, K. and Chan, P. (2006)
Oxidative stress induces nuclear translocation of C-terminus of
alpha-synuclein in dopaminergic cells. Biochem. Biophys. Res. Commun.,
342, 330–335.
87. Zhou, M., Xu, S., Mi, J., Ueda, K. and Chan, P. (2013) Nuclear translocation
of alpha-synuclein increases susceptibility of MES23.5 cells to oxidative
stress. Brain Res., 1500, 19–27.
88. Kontopoulos, E., Parvin, J.D. and Feany, M.B. (2006) Alpha-synuclein acts
in the nucleus to inhibit histone acetylation and promote neurotoxicity.
Hum. Mol. Genet., 15, 3012–3023.
89. Klement, I.A., Skinner, P.J., Kaytor, M.D., Yi, H., Hersch, S.M., Clark,
H.B., Zoghbi, H.Y. and Orr, H.T. (1998) Ataxin-1 nuclear localization and
aggregation: role in polyglutamine-induced disease in SCA1 transgenic
mice. Cell, 95, 41–53.
90. Saudou, F., Finkbeiner, S., Devys, D. and Greenberg, M.E. (1998)
Huntingtin acts in the nucleus to induce apoptosis but death does not
correlate with the formation of intranuclear inclusions. Cell, 95, 55–66.
91. Peters, M.F., Nucifora, F.C. Jr., Kushi, J., Seaman, H.C., Cooper, J.K.,
Herring, W.J., Dawson, V.L., Dawson, T.M. and Ross, C.A. (1999) Nuclear
targeting of mutant Huntingtin increases toxicity.Mol. Cell. Neurosci., 14,
121–128.
92. Takeyama, K., Ito, S., Yamamoto, A., Tanimoto, H., Furutani, T., Kanuka,
H., Miura, M., Tabata, T. and Kato, S. (2002) Androgen-dependent
neurodegeneration by polyglutamine-expanded human androgen receptor
in Drosophila. Neuron, 35, 855–864.
93. Goers, J., Manning-Bog, A.B., McCormack, A.L., Millett, I.S., Doniach,
S., Di Monte, D.A., Uversky, V.N. and Fink, A.L. (2003) Nuclear
localization of alpha-synuclein and its interaction with histones.
Biochemistry, 42, 8465–8471.
94. Siddiqui, A., Chinta, S.J., Mallajosyula, J.K., Rajagopolan, S., Hanson, I.,
Rane, A., Melov, S. and Andersen, J.K. (2012) Selective binding of nuclear
alpha-synuclein to the PGC1alpha promoter under conditions of oxidative
stress may contribute to losses in mitochondrial function: implications for
Parkinson’s disease. Free Radic. Biol. Med., 53, 993–1003.
95. Anderson, J.P., Walker, D.E., Goldstein, J.M., de Laat, R., Banducci, K.,
Caccavello, R.J., Barbour, R., Huang, J., Kling, K., Lee, M. et al. (2006)
Phosphorylation of Ser-129 is the dominant pathological modification of
alpha-synuclein in familial and sporadic Lewy body disease.J.Biol.Chem.,
281, 29739–29752.
96. Emmer, K.L., Waxman, E.A., Covy, J.P. and Giasson, B.I. (2011) E46 K
human alpha-synuclein transgenic mice develop Lewy-like and tau
pathology associated with age-dependent, detrimental motor impairment.
J. Biol. Chem., 286, 35104–35118.
97. Smith, W.W., Margolis, R.L., Li, X., Troncoso, J.C., Lee, M.K., Dawson,
V.L., Dawson, T.M., Iwatsubo, T. and Ross, C.A. (2005) Alpha-synuclein
phosphorylation enhances eosinophilic cytoplasmic inclusion formation in
SH-SY5Y cells. J. Neurosci., 25, 5544–5552.
98. Ishii, A., Nonaka, T., Taniguchi, S., Saito, T., Arai, T., Mann, D., Iwatsubo,
T., Hisanaga, S., Goedert, M. and Hasegawa, M. (2007) Casein kinase 2 is
the major enzyme in brain that phosphorylates Ser129 of human
alpha-synuclein: Implication for alpha-synucleinopathies.FEBSLett.,581,
4711–4717.
99. Wakamatsu, M., Ishii, A., Iwata, S., Sakagami, J., Ukai, Y., Ono, M.,
Kanbe, D., Muramatsu, S., Kobayashi, K., Iwatsubo, T. et al. (2008)
Selective loss of nigral dopamine neurons induced by overexpression of
truncated human alpha-synuclein in mice.Neurobiol. Aging, 29, 574–585.
100. Marley, J., Lu, M. and Bracken, C. (2001) A method for efficient isotopic
labeling of recombinant proteins. J. Biomol. NMR, 20, 71–75.
101. Delaglio, F., Grzesiek, S., Vuister, G.W., Zhu, G., Pfeifer, J. and Bax, A.
(1995) NMRPipe: a multidimensional spectral processing system based on
UNIX pipes. J. Biomol. NMR, 6, 277–293.
102. Johnson, B.A. and Blevins, R.A. (1994) NMR view: a computer
program for the visualization and analysis of NMR data. J.Biomol.NMR,4,
603–614.
103. Kjaergaard, M. and Poulsen, F.M. (2011) Sequence correction of
random coil chemical shifts: correlation between neighbor correction
factors and changes in the Ramachandran distribution. J. Biomol. NMR, 50,
157–165.
104. Steiner, P., Sarria, J.C., Glauser, L., Magnin, S., Catsicas, S. and Hirling, H.
(2002) Modulation of receptor cycling by neuron-enriched endosomal
protein of 21 kD. J. Cell. Biol., 157, 1197–1209.
Human Molecular Genetics, 2014, Vol. 23, No. 17 4509
